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Characterization of the Gonococcal Calprotectin Zn -Acquisition System, TdfH, and
the Efficacy of Metal Starvation for Treating Gonococcal Disease.
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Neisseria gonorrhoeae, the bacterial agent that is responsible for the human disease
gonorrhea, has had a steady increase in the number of infections per year. In 2018 the WHO
estimated over 87 million infections occurred world-wide, and the CDC estimated that over
800,000 infections happened in the United States. Accompanying the increase in gonococcal
infections per year is the increase in the number of antibiotic resistant isolates being recovered.
The recent recovery of a gonococcal isolate that was resistant to the current CDC recommended
dual-treatment, coupled with the lack of a preventative vaccine, marks the beginning of an era
where there may be no effective treatments for gonococcal disease. The gonococcus possesses a
conserved set of proteins that enables it to pirate metal ions from host proteins, and is essential in
order for N. gonorrhoeae to establish an infection in the human urogenital tract. The importance
of TdTs for gonococcal survival and their sequence conservation make them ideal candidates to
be included in a gonococcal vaccine, or as targets for potential new therapeutics that are capable
of disrupting the interaction with their ligands. In this study we developed a competition assay
and probed gonococcal cells with either human (hCP) or mouse calprotectin (mCP) to determine
if the gonococcus is species restricted for its ligand interaction. We also performed Isothermal
Titration Calorimetry experiments to characterize the binding affinity between the gonococcal
calprotectin (CP) binding protein TdfH and calprotectin. In this study we also continued a
mutational and small molecule analysis of TbpA aimed at disrupting the interaction with its
ligand, human transferrin (hTf). Finally, we investigated if the gonococcal efflux pump, MacA,
was responsible for heme export via heme-dependent growth assays of a MacA deficient
gonococcal strain. We report that the interaction between TdfH and hCP is high affinity and that
the Zn piracy of TdfH occurs optimally at the non-canonical metal binding site of hCP known as
xvi

site 1. We determined that multiple mutations, both in the loop 3 helix and in loop 2 of TbpA,
minimally reduce the total binding of hTf, similar to what Cash et al. has previously described. A
screening of a database of small molecules found that several first-generation small molecules
were able to significantly reduce the ability of TbpA to interact with hTf. Finally, we found that
the efflux pump MacA, does not meaningfully contribute to gonococcal heme export. However,
more in-depth studies interrogating MacA substrates are still needed. These studies determined
the species specificity of the gonococcal calprotectin binding protein and found that Zn- piracy
occurs optimally from one specific site on hCP. This study also shows the promise in investing
in new therapeutics that disrupt TdT function.

xvii

Chapter 1: Introduction

I.

Neisseriaceae
The family of Neisseriaceae contains the genera of Neisseria, Moraxella, Kingella,

Acinetobacter, and Eikenella. The organisms within these genera are Gram-negative and have a
characteristic oxidase-positive phenotype. The genus Eikenella and the genus Kingella are
predominated by commensal species found in the human oral cavity and bowel. Opportunistic
infections by Kingella and Eikenella species are rare but do occur. Kingella species infections
occur commonly in bones, joints, and tendons, while Eikenella is recovered most commonly
from an infection after a being bitten by a human. Moraxella species are largely nonpathogenic,
with several species considered as parasites of human mucosal surfaces (1). Moraxella spp. were
once a part of the genus of Neisseria. However, studies into Moraxella DNA content, fatty acid
content, and transformation competence determined that their classification into a separate genus
was more appropriate and prompted the transfer of Moraxella spp. into the family of
Moraxellaceae (2-4). The last genus in the family Neisseriaceae is the genus Neisseria. The
human-associated Neisseria spp. are often identified by their acid-producing capabilities from
glucose or maltose and the ability to reduce nitrite (2). A genomic analysis of the commensal and
pathogenic Neisseria found a difference in the reductive nitrate capacities been Neisseria spp.
Only N. mucosa was capable of nitrate reduction to nitrite. The ability to reduce nitrite to nitric
oxide was a common feature of pathogenic and commensal Neisseria (5).
II.

Pathogenic Neisseria
While the majority of Neisseria species are commensal bacteria of the nasopharynx, they

do have the potential for opportunistic infections (6). Commensal organisms have been
recovered from disseminated sites such as blood and CSF despite not being associated with
1

disease (2,7). Two pathogenic Neisseria species are responsible for the majority of the Neisseria
infections among humans. Neisseria meningitidis and Neisseria gonorrhoeae are obligate
human pathogens that colonize the human nasopharyngeal tract and urogenital tract,
respectively. N. gonorrhoeae is always pathogenic, and the presence of the gonococcus in the
urogenital tract is associated with human disease. N. meningitidis, on the other hand, is capable
of long-term carriage on the nasopharyngeal tract and results in disease only after invasion into
the blood. The gonococcus and meningococcus are non-motile, Gram-negative, catalase-positive
diplococci that grow optimally between 35-37oC and require CO2, which is especially crucial
during the early phases of growth (2,8). While there are differences in the epidemiology of these
infections, the morphological feature that distinguishes between N. meningitidis and N.
gonorrhoeae is the antiphagocytic polysaccharide capsule produced by N. meningitidis (9).
III.
Meningococcal Disease
A. Epidemiology
Neisseria meningitidis is associated with carriage and colonization of the human
nasopharyngeal tract (10). The carriage rate among the human population is quite variable but
can reach upwards of 10-35% in young adults and as high as 80-90% during epidemic outbreaks
in Africa (10-12). Transmission of the meningococcus occurs through direct contact with an
infected person or their respiratory droplets. In closed or semi-closed environments like military
barracks and in-residence college dorms, the meningococcal carriage rate can reach 100% (13).
The incidence of meningococcal disease is the highest among infants, with a secondary spike in
disease prevalence occurring between adolescence and early adulthood. The incidence of
meningococcal disease can vary widely, ranging from 1-1000 cases per 100,000 population/year
with the latter number of cases per year being due to localized outbreaks (13,14). The most
prevalent occurrences of epidemic meningitis are found within the meningitis belt spanning
2

across western and central Africa. Epidemic meningococcal disease in the meningitis belt occurs
at the end of the dry season, where cases can reach upwards of 1000 cases per 100,000
population (13).
Meningococcal capsular polysaccharides are the basis of molecular serogrouping for the
organism. There are 13 different serogroups of N. meningitidis with A, B, C, W, and Y being the
most frequent causes of invasive human disease worldwide (13,15). The capsular
polysaccharides, except for serogroup A, are composed of sialic acid derivatives (14). Serogroup
B polysaccharide is composed of sialic acids with α2-8 linkages and is the major cause of disease
for Europe, Australia, New Zealand, and the Americas (15,16). Serogroup C polysaccharide
connections are composed of α2-9 linkages that are also capable of O-acylation. Serogroup C is
prevalent within populations of Asia and the Americas with a minor contribution to disease
prevalence in Africa. Serogroup Y is composed of an alternating sequence of D-glucose and Oacylated NANA and can represent a major cause of infections in some countries of the Americas
(15,17). Serogroup W polysaccharide only differs from Y polysaccharide by the lack of Oacylation. Serogroup W is the most recent addition to the invasive meningococcal disease group
but has spread quickly and is a prevalent cause of infection for Africa and an increasing threat in
the Americas (15). Serogroup A is composed of repeating units of (α)-linked N-acetylmannosamine-1-phosphate, and the prevalence of the disease that it causes is highest in Asia and
Africa (15,16).
B. Disease
Meningococci utilize pilin and opacity associated proteins as adhesins for colonization of
the nasopharyngeal mucosal epithelium. This binding stimulates the mucosal epithelium to
engulf the meningococcal cells, which may then traverse via phagocytic vesicles through
3

epithelial tissue (18). In a small percentage of colonized individuals, meningococci
dissemination into the bloodstream occurs and causes meningococcal disease. Meningitis occurs
in patients suffering from meningococcal disease and presents with the classical onset of
meningitis symptoms (19). While positive cultures of N. meningitidis have been isolated from
the blood of patients suffering from meningitis, only in 5-20% of cases does meningococcal
sepsis, also known as meningococcemia, occur. Meningitis presents with a rapid onset of
symptoms such as headache, stiff neck, photophobia, nausea, and vomiting. Meningococcemia
may also present with a petechial rash and hypotension, which can result in multi-organ system
failure. Typically, these classical symptoms are seen with young adults and elderly patients.
Young children and infants suffering from meningitis present with atypical symptoms, including
bulging fontanelle, floppy limbs, lethargy, and high-pitched crying (20,21). Prognosis of
meningococcal disease improves with early detection; however, meningitis case fatality rates
range from 9-12%, with meningococcemia fatality rates as high as 40%. Within the population of
surviving patients, 11-19% can suffer secondary sequelae such as hearing loss, neurologic
disability, and loss of a limb (18,21).
C. Treatment and Prevention
Before the availability of antibiotics to treat infectious disease, meningococcal disease
reached almost 100% fatality. Over the past few decades, clinicians, through the use of
antibiotics, have been able to reduce the fatality rate of meningitis to around 9-12%.
Sulfonamides were the first described antibiotics used to treat meningitis in the 1930s’; however,
a rise in antimicrobial resistance forced the switch to penicillin, which is still used as the
recommended therapy today (18,22). Caretakers and individuals that are in close proximity to an
infected person are at an increased risk of infection. Most secondary cases of infection occur
4

within 5-10 days of exposure, and thus prophylactic antibiotics are prescribed for caretakers and
household members of infected individuals to decrease their risk of infection (22). Systemically
acting antibiotics that are capable of preventing meningococcal carriage like rifampicin is the
optimal prophylactic antibiotic. While antibiotic-resistant meningococcal isolates are rare, they
are beginning to emerge (22-25).
Vaccination has been the most effective means of preventing meningococcal disease
worldwide. Since the early 1970s, the bivalent (A, C) and a quadrivalent (A, C, W, and Y)
polysaccharide vaccine (MSPV4, Sanofi Pasteur) have been used to prevent N. meningitidis
infection (26). However, the polysaccharide composition of these vaccines produced a T cellindependent immune response, and after the first year of immunization, antibody titers began to
decline (27). The polysaccharide only vaccine also did not prevent the future carriage of N.
meningitidis, which allowed for meningococcal colonization and infection as a person’s antibody
titer declined if a booster vaccination was not administered (28,29). In 2005, the meningococcal
quadrivalent conjugate vaccine (MenACWY, Menactra) was licensed for use in the United States
(30). The Serogroup A, C, W, and Y capsular polysaccharide conjugate vaccine allowed for a T
cell-dependent immune response resulting in a longer-lasting immune memory than its
predecessor and preventing meningococcal carriage (31). The Advisory Committee on
Immunization Practices (ACIP) now recommends the MenACWY vaccination as part of routine
childhood vaccination with a booster at college age (32,33).
In recent years, N. meningitidis serogroup B has accounted for 32% of meningococcal
disease reported in the United States and between 45-64% of meningococcal disease in Europe,
Australia, and New Zealand (34,35). N. meningitidis serogroup B has been difficult to develop a
vaccine for due to its polysaccharide structure, which is identical to the polysialic acid found on
5

many human glycoproteins. The mimicry of human proteins seen with serogroup B capsular
polysaccharide makes the use of a polysaccharide-protein conjugate vaccine ineffective (34). To
this end, the multivalent outer membrane vesicle (OMV) based vaccine Bexsero
(GlaxoSmithKline), was licensed in the United States in 2014 for the prevention of N.
meningitidis serogroup B disease (36). The 4CMenB vaccine (Bexsero) contains 4 major
meningococcal outer-membrane proteins and detoxified outer membrane vesicles (OMV). N.
meningitidis surface-exposed proteins are highly variable, which necessitates that the chosen
antigens be able to induce cross-reactive antibodies for a majority of the invasive meningococcal
strains (37-40). The principle antigen of the vaccine is PorA, however, reverse vaccination
studies found that the inclusion of Neisseria adhesion A (NadA), factor-H binding protein
(FHbp) fused with GNA2091, and Neisseria heparin binding antigen (NHBA) fused with
GNA1030, all presented with detoxified OMVs isolated from the New Zealand outbreak strain
NZ98/254 would allow for immunogenicity across strains (35,36). Trumemba® (Pfizer) is also a
Serogroup B vaccine that uses the FHbp variants (A05 and B01) and was licensed for use in
2014 in the United States (35). The 4CMenB vaccination has not been associated with any
significant safety concerns, and the majority of adverse reactions relates to local reactions (41%)
or fever (40%) (41). The 4CMenB vaccine can be administered concomitantly with other routine
vaccinations, but the current US recommendation is vaccination with 4CMenB at age 16 (42)
and is not associated with an increased risk of adverse effects after immunization (AEFI) (43,44).
The implementation of the group B vaccine is a promising move forward; however, further
studies at monitoring the long-term efficacy of these vaccines for their decline in antibody titer
and AEFI are still required.
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IV.

Gonococcal Disease

A. Epidemiology
The second of the two pathogenic Neisseria spp. is Neisseria gonorrhoeae, which is the
bacterium responsible for the sexually transmitted infection (STI) gonorrhea (45). N.
gonorrhoeae infections have steadily increased worldwide, with the World Health Organization
(WHO) estimating over 86.9 million cases globally, and 583,000 reported cases in the United
States. Gonorrhea is the second most commonly-reported infectious disease in the U.S. (45). N.
gonorrhoeae is an obligate human pathogen and predominantly spread through direct sexual
contact. Factors such as age, race, sexual orientation, and socio-economic status play significant
roles in the spread of the disease. Individuals between the age of 15-29 are at the highest risk for
contracting gonorrhea, and that risk is also influenced by the number of sexual partners an
individual has (45). Individuals of African descent and Native Americans accounted for the
largest demographic of infected individuals in 2018. In populations of men who have sex with
men (MSM), infection rates continue to rise, and there is an increased risk associated with HIV
infections due to the increase in HIV viral replication seen with gonococcal coinfection (45-48).
A disparity between the number of asymptomatic infections and the reported infection rates of
men and women has also been documented. There are more reported cases of N. gonorrhoeae
infections in men compared to women. However, over 50% of infections in women are
asymptomatic and, thus women often do not seek treatment. The asymptomatic nature of female
infection is believed to make women important reservoirs of N. gonorrhoeae and contribute to
increased morbidities such as pelvic inflammatory disease (PID), ectopic pregnancy, and
infertility as well as the continued spread of the bacterium within the population (48,49).
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B. Disease
Primary infections with N. gonorrhoeae can result in urogenital, anorectal, pharyngeal,
and conjunctival infections (50). Most men infected with N. gonorrhoeae present with
symptoms, including dysuria and urethritis. In 10% of cases, men are asymptomatic, which can
result in an ascending infection manifesting as prostatitis and epididymitis (51). Infections in
women typically present as cervicitis manifesting 5-10 days post-infection, but over 50% of
women are asymptomatically infected (52). Since asymptomatic infections remain untreated
serious secondary sequelae can emerge. The infection can ascend the reproductive tract resulting
in pelvic inflammatory disease, salpingitis, and damage to the fallopian tubes that can result in an
ectopic pregnancy (51). Pharyngeal infections in both men and women are asymptomatic in 90%
of cases and are more difficult to diagnose and treat compared to urogenital infections (53,54).
Rectal infections are also difficult to diagnose due to them commonly being asymptomatic but
can be treated with antibiotics as effectively as urogenital infections. Symptoms of rectal
infections can vary dramatically from mild discharge and itching to overt proctitis (55).
The lack of a protective immune response after N. gonorrhoeae infection is a hallmark of
disease and allows for repeated infections of a person with the same strain of N. gonorrhoeae.
Interestingly, the gonococcus has been documented to upregulate Th-17 and T-regulatory
responses, skewing the immune system away from a protective Th-1 or Th-2 responses (56,57).
Gonococcal promotion of a Th-17 response recruits polymorphonuclear cells (PMN) to the site
of infection, which is an innate response that is more to the gonococcus benefit. The gonococcus
is able to survive inside these recruited PMNs, and survive oxidative bursts generated by PMNs,
which makes these recruited PMN ineffective at controlling gonococcal infections (58).
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C. Treatment
N. gonorrhoeae has shown a remarkable ability to gain resistance to antibiotics, which
began in the early 1930s when sulfonamides were first prescribed to treat gonococcal infections.
Within 10 years of sulfonamide implementation, highly-resistant strains had begun to emerge,
which prompted the shift by clinicians to prescribe penicillin for treatment (59). Since that time,
the steady increase in antimicrobial resistance (AMR) in gonococcal isolates slowly chipped
away at clinically-useful antibiotics intended to treat gonococcal disease (60). The WHO and
Centers for Disease Control and Prevention (CDC) recommend that treatment options be
accessible to all populations and have a 95% cure rate when given as a single dose (45,59). In
2014 the CDC removed fluoroquinolones as a recommended treatment for gonococcal infection,
leaving only a few clinically-useful antibiotics. The current CDC-recommended treatment is dual
therapy of 250 mg of intramuscular ceftriaxone and 1 g oral azithromycin. This treatment is in
line with the ability to effectively treat pharyngeal gonococcal infections and chlamydial
coinfections (61,62). A recent case involving a patient infected by a strain exhibiting high levels
of resistance to ceftriaxone and azithromycin marks the beginning of an era where no clinically
viable treatment for gonococcal disease may exist (61). Given the emergence of high levels of
resistance to third-generation cephalosporins, specifically ceftriaxone, studies investigating
alternative therapies have been conducted. The in vitro synergy of either gentamicin/
azithromycin or gemifloxacin/azithromycin were found to effectively clear urogenital,
pharyngeal, and rectal infections with minimal adverse effects post-treatment (63). It is a top
priority of the WHO to reduce the global incidence of ceftriaxone resistance in order to maintain
a viable treatment for gonococcal disease. The combined issue of the lack of a protective
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immune response and dwindling treatment options makes it critical for future investment into
new therapies and treatments for this infection.
V.

N. gonorrhoeae Virulence Factors

N. gonorrhoeae possesses an array of virulence factors that assist in adherence, infection,
and immune evasion (Figure 1). On top of the numerous gonococcal surface structures, the
regulation of these structures plays an important role in immune invasion. Many of these surface
structures are subject to phase variation, acting to modify protein expression and protein level.
Further, gonococcal surface structures are highly variable, enabling immune invasion.
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Figure 1.) Overview of N. gonorrhoeae Virulence Factors. Image of a gonococcal cell depicting
several surface exposed virulence factors expressed by N. gonorrhoeae. Image adapted from (64)
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A. Type IV Pilus
Neisserial type IV pili are hair-like extensions that are approximately 6 nm in diameter and
can extend for several micrometers away from the diplococcus (65). The type IV pilus is
essential to infection and allows for the colonization of mucosal surfaces. Gonococcal pilin
synthesis requires 23 genes and occurs in 4 steps: assembly, functional maturation, counterretraction, and emergence on the cell surface (66,67). PilE is an 18-22 kDa protein and is the
major structural component of gonococcal pilin that assembles into a helix to generate the pilus
structure. Adhesion to cervical epithelial tissue and microcolony formation is mediated by these
assembled pili (66). The minor pilin proteins PilC, PilV, and PilX, can also be incorporated into
the mature pilus structure; these minor pilins modulate the function of the type IV pilus (68,69).
The pilus of N. gonorrhoeae undergoes high-frequency antigenic variation through nonreciprocal gene conversion. Non-reciprocal gene conversion is RecA-dependent and occurs
between pilS (silent genes) with the pilE structural gene, resulting in an antigenically new pilin
protein. The gene conversion of pilE happens at a frequency of 10-2 cells (70,71). PilE is also
subject to high-frequency phase variation through a polyC tract found within pilE. Slip-strand
mispairing results in frameshifts that can generate early stop codons, which alter gonococcal
pilus production. PilE is also subject to post-translational modifications such as glycosylation,
which further modulates pilin function during infection (72). N. gonorrhoeae pilin protein is a
multi-functional protein, as it is not only necessary for adhesion to host cells during infection but
has also been found to bind extracellular free DNA (73,74). The DNA binding of the gonococcal
pilus has a connection to the natural competency and transformation ability that is characteristic
of Neisseria species (66).
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B. Lipooligosaccharide (LOS)
Lipopolysaccharide (LPS) is a common feature of the outer membrane of Gram-negative
bacteria. LPS is composed of three moieties, lipid A, a core polysaccharide, and O antigen. Lipid
A acts as the outer-membrane anchor for LPS, the core polysaccharide is a short oligosaccharide
motif, and O-antigen is a variable-length polysaccharide that extends away from the bacteria
(75). N. gonorrhoeae LPS lacks the variable-length O-antigen, unlike LPS of enteric bacteria,
and is often referred to as lipooligosaccharide (LOS). LOS of N. gonorrhoeae is also able to
antigenically vary itself at high frequency through the phase-variability of glycosyltransferases
that are responsible for catalyzing the extension of the LOS carbohydrate chain (76). Three such
glycosyltransferases, lgtA, lgtC, and lgtD, have polyG tracts that allow for slip-strand mispairing
during DNA replication (77).
The antigenic variability of LOS is just one way that the gonococcus can subvert immune
detection. LOS undergoes sialylation through host cytidine5′-monophospho-N-acetyl neuraminic
acid (CMP-NANA). Sialylation of gonococcal LOS allows for host Factor H binding protein
(FHbp) deposition and confers serum resistance to the bacteria. However, the sialylation of LOS
only occurs with certain variants and is considered phase variable due to the phase variability of
the glycosyltransferases responsible for extending residues capable of being sialylated (78,79).
Interestingly, the sialylation of gonococcal LOS interferes with gonococcal invasion of certain
cell types. Invasion through epithelial tissue may promote the population of cells that become
serum resistant through the sialylation of specific LOS variants and provides an explanation for
the phase variable nature of LOS (80).
The LOS structure of N. gonorrhoeae is immunochemically identical to various human
glycosphingolipids and glycolipids (81). Gonococcal LOS that mimics paragloboside is also
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capable of binding to asialyoglycoprotein receptor (ASP-R) found in the male urethral
epithelium and promotes intracellular invasion. The invasion of male urethral cells by the
gonococcus is predicted to aid in disease spread due to the presence of ASP-R positive urethral
cells found in urethral exudate (82,83). A link between heptose derived from gonococcal LOS
and an increase in HIV-1 viral replication underscores the public health importance that this
pathogen has for other diseases pathology (84).
In addition to LOS sialylation, neisserial LOS has been shown to be decorated with
phosphoethanolamine (PEA) via the PEA Transferase A [lptA, (85)]. PEA decoration of
gonococcal LOS has been found to provide the gonococcus resistance to the bacterial derived
cationic antimicrobial peptide (CAMP) polymyxin B, specifically when PEA is catalytically
added to the 4’ position of gonococcal lipid A (85). The presence of PEA modification of LOS
has been associated with resistance to complement mediated killing when found within the
gonococcus but not the meningococcus (86,87). Further, the presence of PEA decorated LOS
increases the induction of proinflammatory cytokines, such as TNF-α, which is driven by Tolllike receptor 4 (TLR4) signaling (88). PEA decoration of gonococcal LOS has been shown to
have a dual immunostimulatory and protective role during infection. Gonococcal cells that were
unable to express lptA were at a competitive disadvantage during a genital tract infection of
Balb/C mice, and demonstrates that the importance that PEA decoration of LOS has during
infection (89). Interestingly, lptA was reported to only be found in the genome of the pathogenic
Neisseria and N. lactamica, a commensal Neisseria (90). The absence of the lptA gene in the
genome of the commensal Neisseria has been hypothesized as a mechanism that has allows for
commensals to remain within the host without inducing the protective host response (90).
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C. Porin
Porin is a major component of the gonococcal outer-membrane constituting about 60% of the
outer membrane total protein content (91). Neisserial porins form trimeric complexes in the outer
membrane. Each monomer forms a β-barrel in the outer membrane (92,93). Porins are essential
to the survival of Neisseria spp. and function as pores that allow ions and small nutrients across
the membrane (94). N. meningitidis encodes two porins in its genome. Class 1 porin is
commonly referred to as PorA and is the larger of the two porins at around 45 kDa and phase
variable. Class 2 and 3 porins, or PorB, is smaller at around 33-35 kDa (95,96). N. gonorrhoeae
PorA exists as a pseudogene due to mutations in the promoter and coding regions and thus is
only capable of expressing PorB (94,97). Gonococcal PorB can be further classified into two
subgroups of protein 1A (PorB1A) and protein 1B (PorB1B) (94).
Por1A is associated with an invasive phenotype and increased resistance to killing by
complement. The expression of Por1A may be associated with a tendency to cause disseminated
infection based on epidemiological evidence (98). Additionally, gonococcal porins can aid in
pathogenesis through the insertion into host cell membranes. This insertion results in a pore
within eukaryotic cell membrane that changes the charge of the cell membrane interfering with
host cell signaling (99). Gonococcal porins inserted into the membrane of the phagosome prevent
their degranulation and maturation, independent of NADPH activity. The lack of maturation is
thought to promote intracellular survival of N. gonorrhoeae that have been phagocytosed by
neutrophils and macrophages (100,101).
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D. Opacity (Opa) Proteins
Opacity (Opa) proteins are a family of outer membrane proteins that mediate tight adherence
and transcytosis of epithelial cells and leukocytes (102,103). Opa proteins consist of 8
transmembrane domains and 4 surface-exposed loops, which contain two hyper-variable regions
and a semi-variable domain. The hyper-variable region and semi-variable domain increase the
number of unique Opa alleles that N. gonorrhoeae or N. meningitidis can express through
intergenic and interstrain recombination of Opa proteins (65,104). The number of opacity
proteins encoded in the genome of N. gonorrhoeae and N. meningitidis differs, with the
gonococcus encoding ~11 different Opa proteins and the meningococcus encoding between 4
and 5 different Opa proteins. Every Opa gene sequenced to date contains a pentameric
pyrimidine tandem repeat (CTCTT)n that is present within the 5’-region of the signal peptide
coding sequence for gonococcal and meningococcal Opa proteins. These pentameric repeats
allows for high-frequency phase variation via slipped-strand mispairing resulting in a
heterogeneous population of cells expressing none, one, or multiple different Opa proteins
(105,106).
The critical functions of the Opa proteins are highlighted by their expression during both
experimental and natural infections (107,108). An experimental infection study of human male
volunteers found that the initial inoculum of mostly Opa negative cells was recovered as Opa
positive, indicating a strong selective pressure for Opa expression during infection (109). Opa
proteins have been found to play a multi-factorial role during gonococcal and meningococcal
adherence and invasion, and the compliment of Opa proteins expressed is the ultimate
determinant of these roles (110). Opa proteins allow for the tight adherence to multiple cell types
including epithelial cells and various immune cells (111). Opa proteins have a receptor tropism
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for carcinoembryonic antigen cell adhesion molecule (CEACAM) and heparin sulfate
proteoglycans (HSPG), which are responsible for the neisserial range of cellular adherence and
disease pathology (112-116). Opa-CEACAM5 interaction on vaginal epithelia promotes long
term lower-genital tract colonization. However, the interaction of Opa-CEACAM 1 on uterine
epithelia enhances gonococcal penetration of the tissue (117). Despite the positive benefit that
Opa-CEACAM interactions have for N. gonorrhoeae, Opa binding to CEACAM 3 expressed on
the surface of neutrophils enhances their phagocytosis and killing. Thus, the Opa variants present
within the infecting population and the population of CEACAM expressing cells within the
infected tissue greatly determines the outcome of infection (117-119).
Beyond the multi-factorial adhesion properties of Opa proteins, they also provide the
gonococcus with the ability to modify the immune response to prevent a protective response.
Opa 1 interaction with B-cells expressing CEACAM 1 induces cellular death of those B-cells
and results in lower overall antibody production during gonococcal infection (120). Similarly,
gonococcal cells can selectively suppress CD4+ T- lymphocytes activation and proliferation
through the interaction of Opa 52 with CEACAM 1 (121). In addition to the cellular inhibition
mediated by gonococcal Opa proteins, they can also manipulate the immune environment by
interaction with lymphocytic CEACAMS. Opa mediated interaction of lymphocytes induces the
production of TGF-β and IL-10, allowing for suppression of a protective Th-1/Th-2 response and
promotes a Th-17 immune response, which is ultimately to the benefit of the gonococcus
(56,57,122).
VI.

Iron Sources in Humans
Iron is essential for life with very few exceptions and, as such, iron acquisition is

recognized as a key step in bacterial pathogenesis. Iron exists in a readily interchange redox
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state, which is either a ferrous (Fe2+) or ferric (Fe3+) form. The redox potential, ranging from 300 mV to +700 mV, and the abundance of iron during the early evolution of life made it an
ideal candidate for the incorporation into proteins as biocatalysts and electron carriers. Iron’s
biological functions are completely dependent on its incorporation into proteins or more complex
structures such as iron-sulfur clusters or heme groups (123). The chemical properties that make
iron ideal for biological processes also allow for potentially harmful and toxic effects. In aerobic
environments, iron is found predominantly as Fe3+ and has a solubility at pH 7 of 1.4 X 10-9 M
(124). The relative insolubility of ferric iron in the presence of oxygen necessitates the reduction
to its ferrous form. The reduced ferrous form of iron potentiates iron toxicity through its

·

participation in Fenton Reactions (Fe2++H2O2 → Fe3++OH +OH-) and produces hydroxy radicals

that can damage DNA, proteins, and lipids (125).
The aerobic environment of the human body contains ~3.5g of iron, which requires tight
regulation for protection against toxicity (126,127). The sequestration of iron is achieved
intracellularly by ferritin and extracellularly by iron-scavenging or transport proteins (124). Iron
storage proteins leave the human body almost devoid of iron, with free iron levels in plasma
being ~10-18 M (128). These mechanisms for iron sequestration also provide a counter-measure
of defense against invading pathogens. The lack of free iron found within the human body makes
it a hostile environment for bacteria, and the host iron-withholding defenses to these bacteria are
referred to as nutritional immunity (129). In response to invading microorganisms, intestinal
assimilation of dietary iron is reduced, and there is an increased production of iron-withholding
proteins that reduces the free iron levels in the body (130). The ability of a pathogen to acquire
iron and overcome host nutritional immunity is therefore a critical virulence determinant for the
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initiation and continuation of infection (130,131). In the absence of available free iron during
infection, host iron binding proteins act as the bioavailable pool of iron for these microbes.
Described below is a summary description of the iron binding proteins of humans.
A. Transferrin
Human transferrin (hTf) is an 80 kDa glycosylated protein that is synthesized in the liver and
secreted into blood plasma (132). There are two lobes of hTf (N-lobe and C-lobe) believed to
have been generated by an ancestral gene duplication (133). The N- and C- lobe of hTf are both
capable of binding to Fe3+ with an approximate KD of 10-22 M (134). Circulating hTf is
approximately 30% saturated with Fe3+, but that can vary depending on the availability of dietary
iron and the infection status of a person. The serum concentration can also range widely from 2550 μM (135). At any point in time, 4 different species of Fe3+ loaded hTf can exist in circulation,
a monoferric N-lobe, monoferric C-lobe, diferric-hTf (both N and C-lobe have bound to Fe3+), or
apo-hTf (136,137). The N-lobe seems to be bound by a Fe3+ ion at a higher frequency then the Clobe; however, no clear distinction as to the reason or relevance in vivo has been determined
(136,138). All cells that require iron express human transferrin receptor (TFR1) on their surface.
TFR1 interacts with diferric hTf with the highest affinity (~4 nM) at pH 7.4, but both monoferric
forms of hTf do form a high affinity stable complex with TFR1 (~30 nM) at pH 7.4 (139).
Internalization of the TFR1-hTf complex occurs through clathrin-dependent endocytosis leading
to the acidification of the endosome and release of Fe3+ (140). Apo-hTf has its highest affinity for
TFR1 at low pH, which allows for the recycling of hTf back into the serum through displacement
by an iron-containing hTf or its dissociation from TFR1 (141).
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B. Lactoferrin
Human lactoferrin (hLf) is an 80 kDa glycosylated iron-binding protein that belongs to the
transferrin protein family. Similar to transferrin, hLf is bilobed, but the binding site of each lobe
binds to a Fe3+ ion with high affinity and to a CO32+ ion. Other metals, such as Cu2+, Zn2+, and
Mn 2+, have also been documented for their capability to bind to lactoferrin (142). Lactoferrin is
found within mucosal secretions such as saliva, tears, semen, vaginal secretions, and is the
second most abundant protein in milk (143). Serum concentrations of hLf are low (3.8-8.8 nM),
compared to the levels found within mucosal secretions (6-13 μM)(142,144) Neutrophil
secondary granules contain high concentrations of hLf, and this is proposed to have a significant
physiological role during inflammation (145). The capability of hLf to remain bound to iron over
a wide pH range makes it unique among the transferrin protein family (146). During infection, at
local sites of inflammation, hLf levels can reach 200 μg/mL, and aside from its role in iron
homeostasis, hLf has also been documented to be antimicrobial against a broad-spectrum of
pathogenic organisms (147,148). The antimicrobial effects of lactoferrin have been attributed to
two mechanisms with the first being its metal withholding properties. The second is the ability of
cationic peptide formation after proteolytic cleavage of lactoferrin to lactoferricin B. (149,150).
Lactoferricin B has an overall positive charge which allows for interaction with the negatively
charged membrane of pathogens and their associated surface structures like LPS or LTA. The
membrane association of lactoferricin B results in membrane destabilization and enhances other
innate effectors like lysozyme, which results in the death of the pathogen (151,152).
C. Ferritin
When intracellular iron levels are in excess, the potential noxious chemistry is mitigated by
the deployment of ferritins. Ferritin is composed of a 24 subunit heteropolymer of two different
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chains, which are the heavy (H) chain (210 kDa) and light (L) chain (195 kDa). The H and L
chains are both required for the formation of functional, mature ferritin resulting in a spherical
shell which is approximately 450 kDa. The ferritin shell accommodates up to 4500 oxygen and
hydroxyl-bridged iron atoms, though most ferritins that have been isolated contain between 200
and 2500 iron atoms. Ferritins are highly conserved throughout all of life and the need for
ferritins can be demonstrated by the lethality that a ferritin knockout (KO) has in mice (153,154).
Proteasomal degradation of ferritin liberates the sequestered iron and is thought to provide iron
to the cell as available iron begins to dwindle (155). Hemosiderin is a water-insoluble,
degradation product of ferritin. Hemosiderin’s core is more heterogenous then that of ferritin and
allows for a slower release of iron, but iron release from hemosiderin does occur under acidic
conditions (156,157).
D. Heme/Hemoproteins
Approximately 70% of the human body's iron is stored as heme, which is a heterocyclic ring
capable of coordinating one ferric iron atom (158). The heterocyclic ring, also known as
protoporphyrin, is critical for cellular respiration, enzymatic reactions and oxygen transport
throughout the body. Heme is synthesized in a majority of human cell types and can also
potentiate toxicity through the creation of reactive oxygen species (ROS) and lipid peroxidation
(159,160). Given the potential of heme toxicity to cells, 95% of heme is bound to various heme
proteins. The most common hemoprotein is hemoglobin and it accounts for ~65% of the total
hemoprotein in the human body and transported around via erythrocytes (158). Hemoglobin
(Hg) is a tetrameric protein that consists of two α-chains and two β-chains. Each subunit of Hg
binds to a molecule of heme, which in turn binds to oxygen and allows for oxygen transport.
While much of the heme is found intracellularly, spontaneous hemolysis of red blood cells
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causes the release of Hg, where serum concentrations can range from 8-800 nM (144).
Hemoglobin released through hemolysis can be bound by haptoglobin for eventual recycling by
macrophages or in the liver (161).
E. Siderophores
Siderophores are low-molecular-weight (less than 1 kDa) molecules that are secreted and
utilized by microbes to overcome the iron-limited conditions of the host or the environment
(162). Siderophores have high specificity, and affinity for Fe3+. Strong affinities, ranging from
10-22 to 10-52 M, is enough to remove Fe3+ from host proteins such as ferritin, hTf, and hLf
(124,163). Siderophores are generally produced by large multi-enzyme synthetases that create a
high degree of structural variability in the iron-coordinating residues and can be classified into
one of three categories: catecholate, hydroxamate, and hydroxycarboxylate (162,164).
Siderophores are secreted into the extracellular environment where they scavenge available iron.
Iron loaded siderophores can deliver their iron cargo to microorganisms through siderophore
specific receptors. Some microorganisms co-opt xenosiderophores produced by other bacteria
and therefore have a selective advantage for iron acquisition within a population (164).
In response to siderophore mediated iron piracy, mammalian hosts have evolved an
immune counter-measure: that is, to sequester ferric-siderophores complexes away from their
respective siderophore receptors. These siderophore sequestering proteins belong to the lipocalin
family of binding proteins and are commonly referred to as siderocalins (165). Siderocalins bind
to catecholate-type siderophores, such as enterobactin, with sub-nanomolar affinity and sequester
them so that they are unavailable for bacterial use (165,166). Siderocalin KO mice show a
significant increase in susceptibility to bacterial infection for bacteria that rely on siderophore
mediated iron acquisition (167-169). In response to siderocalins bacteria have evolved modified
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siderophores that sterically hinder siderocalin binding. Pathogenic E. coli and S.
typhimurium both produce salmochelin, a C-glycosylated enterobactin analog, encoded by a five
gene iroA locus. S. enteria also produces salmochelin by incorporating glucose residues on the 5’
of two catecholamide rings of enterobactin to prevent siderocalin chelation of its siderophore
(166,170,171).
VII.

Zinc in the Human Body

The important role of iron for various cellular processes, including energy metabolism
and participating in redox chemistry is well documented an understood (123). Other metals like
magnesium (Mg 2+) or calcium (Ca2+) are known for their roles in enzymatic processes and
cellular signaling (172-174). Zn is another crucially important metal that is capable of
participating in intra- and extracellular signaling and is a catalytic or structural component for
over 3000 human metalloproteins and enzymes (175,176). Zn is distributed among various
locations and organelles in eukaryotic cells with 30-40% of intracellular Zn localizing in the
nucleus, 50% in the cytoplasm and the remaining 10% can be found within the membrane (177).
In the extracellular environment, Zn can signal in an endocrine, autocrine, and paracrine fashion.
Zn that is released into the presynaptic cleft can modulate the postsynaptic transmission and
effect neuronal plasticity (178). Co-release of Zn and insulin from pancreatic β-cells can inhibit
hepatic insulin clearance by inhibiting clathrin-dependent insulin endocytosis (179). Intracellular
Zn acts as a second messenger after it is imported into the cytoplasm or released from organelle
storage (180). Intracellular Zn signaling has been defined into two classes depending on their
timescale, fast or “early” Zn signaling and late Zn signaling. Early Zn signaling occurs within
seconds to minutes and does not require proteins or transcription factors for their signal
transduction (180,181). Late Zn signaling involves the control of intracellular Zn concentrations
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through the synthesis of Zn transport proteins and occurs hours after stimulation (175). Despite
the intracellular Zn concentration being within the range of hundreds of micromolar, the “free”
Zn concentration has been calculated to be in the picomolar range (182). The difference between
total and available (free) Zn concentrations in cells has provided a new perspective on the role of
Zn in cell regulation, cell signaling, and protein interactions (183). The proteins that use Zn as a
catalytic or structural component must have high affinities for Zn in the range of the free Zn
concentrations of the cell. Thus, low-affinity Zn regulatory sites may not be biologically relevant
to cellular regulation and signaling (184). As with many other transition metals, the maintenance
of Zn homeostasis is critical to mitigating the toxic effects that high concentrations can have,
while ensuring enough Zn is present for cellular functions (175).
There are 24 membrane transporters of Zn encoded within the human genome. Out of the
24 transporters, 14 of them are Zrt, Irt-like proteins (ZIPs) and are responsible for Zn import into
the cytoplasm from the extracellular space and cellular organelles (185). The 10 remaining
membrane transporters are the Zn exporters (ZnT), which maintain cytosolic Zn homeostasis by
mobilizing Zn from the cytosol into extracellular compartments or the lumen of cellular
organelles (186,187). The mechanism of ZIP transport has yet to be elucidated; however, the
ZnT transporters belong to the cation diffuser facilitator (CDF) superfamily and uses proton
antiport to drive the transport of Zn into the extracellular and luminal space (188). In addition to
these transporters, metallothionein also aids in regulating cellular Zn homeostasis.
A. Metallothioneins
Metallothioneins are small, low-molecular-weight, cysteine-rich, intracellular, Zn
regulated proteins that can coordinate up to 7 atoms of Zn or other divalent cations like copper
(Cu) or cadmium (Cd) (189). Between 5-15% of cytosolic Zn is bound by metallothioneins and
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they are thought to contribute to Zn signaling by quickly adding or removing free Zn from the
cytosol (190). Interestingly, unlike for iron storage, there is no dedicated high-capacity Zn
storage protein similar to ferritin but the shuttling of Zn into endocytic vesicles may be an
explanation for the lack of such a protein (175).
B.) S100 Proteins
S100 proteins are a family of small (between 10-12 kDa) acidic Ca2+ binding and signaling
proteins that contain 2 EF-hand motifs (191,192). Unlike other calcium signaling proteins, S100
proteins have been shown to act both as intracellular regulators and extracellular signalers. Most
S100 proteins are expressed in a cell-specific manner. Additionally, S100 proteins form obligate
homo or heterodimers with the potential to form higher-order oligomers, which adds to their
functional diversification (191,193). Extracellular S100 proteins are unique in their ability to act
in a cytokine-like manner and interact with receptors for advanced glycation end-products
(RAGE) and result in NF-κB gene transcription. Other than Ca2+ binding, a subset of S100
proteins have been reported to bind to Zn2+, and Cu2+ and this binding contributes to host
nutritional immunity (194).
There are three S100 proteins that have been implicated for their role in nutritional
immunity by virtue of their ability to sequester various transition metals from inflamed tissue
(194). S100A7, also known as psoriasin due to its high concentrations in psoriatic plaques, has
been recently shown have antimicrobial function against E. coli and Pseudomonas aeruginosa
(195). The antimicrobial function of S100A7 has been attributed to Zn limitation and Zn
complementation with excess Zn2+ abrogates S100A7 bactericidal activity (195). However, a
second mechanism of antimicrobial activity has been proposed that relies on direct adherence to
pathogens found on the epidermis to mediate antimicrobial activity (196).
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S100A12 has been difficult to study due to its absence in the genome of mice (197).
However human S100A12 has been found to be antimicrobial against several parasites (198).
The mechanism of S100A12 antimicrobial activity has not been fully identified but studies into
the antimicrobial properties of calcitermin, a protein homologous to the C-terminus of S100A12,
supports the hypothesis of metal sequestration as the mechanism (199). Aside from Zn
sequestration, S100A12 has also been suggested to bind to Copper (Cu2+), which results in the
production of superoxide that contribute to S100A12 antimicrobial properties (198,200).
The last and most well characterized S100 protein with antimicrobial function is
calprotectin (CP). CP is unique among S100 proteins for the preference of S100A8 and S100A9
to heterodimerize, unlike most S100 proteins which are homodimers (201). The unique and
characteristic heterodimerization between S100A8 and S100A9 gives CP the ability to sequester
a wider range of transition metals such as Zn, Mn, Cu, and Fe and makes CP antimicrobial
against a broad spectrum of pathogens (202-205). The binding of Ca2+ to CP allows for the high
affinity transition metal sequestration, and therefore the concentration of Ca2+ modulates the
function of CP (206). When CP is intracellular, concentrations of Zn and Mn are low enough that
even during Ca2+ signaling cascades, CP does not meaningfully contribute to Zn or Mn
sequestration. However, the higher levels of Ca2+ in the extracellular space ensures the activation
of the metal-sequestering antimicrobial properties of CP in the location where it is most likely to
encounter pathogens (206).
VIII.

Metal-Acquisition Systems of N. gonorrhoeae

N. gonorrhoeae has evolved as a human specific-pathogen and is exquisitely adapted for
survival within the human body. As such, it has developed an interesting strategy that allows it to
acquire metals, like iron and zinc, during infection. N. gonorrhoeae utilizes several TonB27

dependent transporters that are highly specific for their human ligands to acquire metals during
infection. TdTs are found as either single-component or two-component systems and hijack host
proteins to remove the metals that are bound to them.
A. Two-Component TonB-dependent Transport Systems
Several TdT systems of N. gonorrhoeae consist of two partners with the first being the TdT
and the second a lipoprotein (Figure 2). Typical TdT structure consists of a 22-stranded
amphipathic β-barrel, 11 flexible loops extracellular loops, and folded plug domain inside of the
barrel, which is located in the outer membrane of the bacteria (207,208). The associated
lipoprotein also located tethered to the outer leaflet of the outer membrane. The transferrin- iron
acquisition system, responsible for binding to hTf and stripping it of its Fe3+, consists of the
proteins TbpA and TbpB (209,210). TbpA is a typical TdT and structurally contains a 22stranded β-barrel, 11 flexible extracellular loops, and a folded plug domain located inside of the
barrel. TbpA/TbpB are encoded in the genome of most Neisseria and found in the genome of all
isolates of N. gonorrhoeae and N. meningitidis (211). The necessity of the transferrin acquisition
system was demonstrated in a human infection experiment where a strain created to be unable to
produce TbpA/TbpB was attenuated for its ability to colonize the male urethra (212). The
lipoprotein TbpB is bilobed with the N- lobe preferentially binding to hTf. tbpA and tbpB are
organized within an iron-regulated bicistronic operon, where tbpB precedes tbpA (213). TbpA
and TbpB are both capable of binding to human transferrin with nanomolar affinity, but only
TbpA is required for the transport of iron across the outer membrane (214). TbpB has been
hypothesized to make the iron acquisition more efficient since TbpB is only capable of binding
to holo-transferrin and its absence results in a lower rate of iron uptake by the gonococcus (215).
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The hLf iron acquisition system of the gonococcus is similar in nomenclature and
structure to the transferrin acquisition system. The hLf acquisition system is comprised of a TdT
termed LbpA and its cognate lipoprotein, LbpB (216,217). lbpA and lbpB, similar to the hTf
system, are organized in an iron-repressed bicistronic operon where lbpB precedes lbpA.
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Figure 1.2.

Two-Component TonB-dependent Transporters of N. gonorrhoeae
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Figure 1.2.

Two-Component TonB-dependent Transporters of N. gonorrhoeae.

Overview of the two component TonB-dependent transport systems: TbpAB, LbpAB, and
HpuAB. The barrels imbedded in the outer membrane (OM) represent the TonB-dependent
transporters (TdTs): TbpA, LbpA, and HpuB. Associated with each of these barrels are the
lipoproteins: TbpB, LbpB, and HpuA. These are attached, through a lipid anchor, to the outer
leaflet of the OM. The ligand for each of the TdTs is shown, with The TbpAB system bound to
human Transferrin (hTf), the LbpAB system bound to human lactoferrin (hLf) and the HpuAB
system bound to hemoglobin (Hb). Iron that is removed from hTf, hLf, and Hb traverses into the
periplasmic space where it is bound by the periplasmic binding proteins FbpA. FbpA shuttles the
iron atom to the ABC transporter FbpB and FbpC embedded on the inner membrane (IM), which
uses cellular ATP to transport the iron atom into the cytoplasm of the gonococcus. The TonB
complex of proteins, which consists of TonB, ExbB, and ExbD, are associated with the IM.
TonB faces into the periplasmic space and interacts with the TonB box found in the plug domain
of each of the TdTs. ExbB and ExbD harness the proton motive force that energizes TonB.
Unlike the hTf system, the hLf system is subject to phase variation due to the presence of a
polyC tract in the coding region of lbpB (216). The hLf system is present in all meningococcal
strains, but in some 50% of gonococcal strains there is a deletion of lbpB and a 5’ portion of
lbpA. The hLf acquisition system is not essential for gonococcal virulence but provides
redundancy for iron acquisition from the host (218).
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The last of the two-component metal acquisition systems of N. gonorrhoeae is the
hemoglobin/ hemoglobin-haptoglobin (Hg-Hp) iron acquisition system. The Hg system gene
nomenclature is reversed from the hTf and hLf systems with the TdT being encoded by hpuB and
the cognate lipoprotein being encoded by hpuA and is found in most Neisseria. The Hg system
has been reported to bind to Hg and Hg-Hp complexes and requires both HpuA and HpuB for
heme uptake and the ability to grow on hemoglobin as the sole iron source (219,220). The Hg
system, similar to the hLf system, is subject to phase variation by a polyC tract in the coding
region of hpuA.
B. Single-Component TonB-dependent Transport Systems
In addition to the two-component systems, Neisseria also encodes single component systems
that lack the lipoprotein of the other transporters (Figure 3). The HmbR Hb acquisition system is
a single-component acquisition system that allows N. meningitidis to acquire heme. The HmbR
system is subject to phase variation via a polyG tract similar to the Hpu system (221,222). The
hmbR gene exists as a pseudogene in N. gonorrhoeae due to the presence of a stop codon in its
coding sequence (223). The iron-regulated xenosiderophore transporter FetA is another singlecomponent system of Neisseria. FetA is a 76 kDa siderophore receptor, which is encoded within
all Neisseria species (211,224). Neisseria species do not produce siderophores themselves but
FetA allows for the gonococcus to use other bacterial siderophores during infection (224). FetA
like most of the outer membrane proteins of N. gonorrhoeae, is subject to phase variation, which
influences the expression level of FetA and depends on the number of cytosine residues between
the -35 and -10 sequences (225). The gonococcus encodes 4 other single-component systems
TonB dependent factor J (TdfJ), TonB dependent factor H (TdfH), TonB-dependent factor F
(TdfF) and TonB-dependent factor G (TdfG).
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Figure 1.3.

Single Component TonB-dependent Transporters of N. gonorrhoeae.

Overview of the Single component transporters, FetA, TdfH, TdfJ, TdfF, and TdfG of N.
gonorrhoeae. The TonB-dependent transporters (TdTs) are barrels traversing the OM with the
associated ligand for each system bound to the top of the barrel. The metal removal from the
ligand results in the periplasmic binding protein sequestering the incoming metal and
subsequently transports the metal to the appropriate ABC transporter. FetA internalizes
xenosiderophores which are bound by the periplasmic binding protein FetB. FetB carries the
xenosiderophore to FetC/FetD for the active transport of the xenosiderophore into the cytoplasm
of the gonococcus. TdfH and TdfJ bind human calprotectin (hCP) and S100A7, respectively. The
zinc associated with these proteins is removed and then shuttled into the periplasm where the
periplasmic binding protein ZnuA binds the zinc atom. ZnuA carries the zinc ion to ZnuB/ ZnuC
for the active transport of Zn into the cytoplasm of the gonococcus. To date neither TdfF nor
TdfG have had their ligand identified, and it is unknown what ABC transport system they are
associated with. TdfF and TdfG are both believed to be involved in iron homeostasis, and TdfG
is the largest of the known gonococcal TdTs. TonB/ExbB/ ExbD is not depicted; however, they
are required for FetA, TdfH, TdfJ, TdfH, and TdfG function.
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Only TdfG remains uncharacterized, and is the largest of the TdTs encoded on the
gonococcal genome at 130 kDa. While the ligand of TdfG remains unknown, it is iron-regulated
and is primarily encoded in the genome of the gonococcus (226). The expression of TdfF is
unique compared to the other TdTs of the gonococcus. TdfF was only expressed when gonococci
were grown in cell culture medium supplemented with fetal bovine serum (FBS) and only found
among the pathogenic Neisseria. Interestingly, TdfF was the only TdT that was important for the
intracellular survival of the gonococcus during experimental infection of cervical epithelial cells
and tdfF expression was upregulated in the absence of iron (227). The remaining two single
component transport systems are unique for their role in zinc acquisition.
Initial studies into the function of the TdTs found that TdfH was not responsive to
cellular iron levels, but TdfJ expression was enhanced in the presence of iron. This evidence
suggested that the roles of these TdTs were for something other than iron transport (228).
Gonococcal TdfJ and its homolog in N. meningitidis, ZnuD, are regulated via the zinc uptake
regulator (Zur) (229). Recently, a detailed study of TdfJ elucidated that its interacting partner is
the innate immunity protein S100A7 and its expression was enhanced in the presence of iron
under Zn deplete conditions. Like almost all interactions between gonococcal TdTs, the
interaction between TdfJ and S100A7 is human restricted, and mouse S100A7 was unable to
support the growth of the gonococcus as the sole zinc source (230). TdfJ is regarded as a
potential vaccine target due to the lack of known phase variation and its conservation within
Neisseria (229).
The final single-component system of N. gonorrhoeae is the calprotectin binding and Znuptake system, TdfH, or CbpA for the meningococcal homolog. Similar to TdfJ, TdfH is subject
to Zur regulation and repressed in the presence of Zn. The heterodimer of S100A8 and S100A9,
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known as calprotectin, which is the ligand for TdfH, is abundant in inflamed tissue and has two
high-affinity binding sites for Zn (202,205). The interaction between TdfH and calprotectin
allows for gonococcal survival of neutrophil extracellular traps (231).
C. TonB-Dependent Transport
The transport systems described above are all members of the TonB dependent family of
outer-membrane receptors. The transport of the heme, iron chelates, Fe, and Zn through the βbarrel of these transporters requires energy that is mobilized through the TonB-complex
(232,233). The TonB complex is a tripartite system of proteins consisting of TonB, ExbB, and
ExbD located in the periplasmic membrane. TonB, ExbB, and ExbD are encoded on the
gonococcal genome in an iron-repressed operon (234). TonB has 3 functional domains: an N
terminal transmembrane domain, a proline-rich spacer that allows for the protein to extend into
the periplasmic space, and a C-terminus that interacts with the TonB box present on the plug
domain of the TonB receptor (207,235). TonB harnesses the energy from a proton motive force
(PMF) and through the interaction of TonB with the TonB box, the energy from the PMF enables
the acquisition of metal substrates through a yet undetermined mechanism (236).
D. Cytoplasmic transport
After the import of the metal nutrients through the TonB outer-membrane receptors, the
transport of these nutrients to the cytoplasm is facilitated through a set of periplasmic binding
proteins (PBP), an inner membrane permease and ATP-binding cassette (237). Iron transport in
the periplasm from hTf and hLf is accomplished via the ABC transport system of FbpABC.
FbpA is the PBP and when unbound by Fe3+, is hypothesized to interact with TbpA and drive Fe
transport through TbpA due to its affinity for Fe3+ (~10-18 M) (238,239). There is a separate ABC
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transport system FetCDEF, which allows for the utilization of enterobactin and requires the PBP
FetB (240,241). No dedicated heme transport system has been discovered in Neisseria but the
presence of a heme ABC transport system is hypothesized to exist. The ZnuABC transport
system allows for the import of Zn and is Zur regulated in N. meningitidis (242). ZnuA is the
PBP and is required for the growth of the gonococcus on S100A7 and Calprotectin (230).
E. Regulation
The ability of an organism to sense their metal environment and respond during periods
of high and low concentrations is critical for their survival and the virulence for pathogens. The
iron acquisition systems of N. gonorrhoeae and their regulation is crucial for maintaining enough
iron to grow and survive, but not allow for toxic accumulations (243). Thus, regulation of the
iron acquisition systems is driven by the ferric uptake regulator (Fur) and is a part of a global
iron regulatory network called the Fur regulon (244). When cellular concentrations of iron are
high, monomeric Fur interacts with ferric iron to make dimeric Fur. The dimer is the functionally
active form and binds to Fur boxes on the DNA of genes in the Fur regulon to regulate
transcription (245). Traditionally this regulation was the repression of genes when iron stores
inside of the cell were high. As the intracellular stores of iron were used, the repression was
relieved due to a lack of iron capable of dimerizing Fur (246). Studies with N. meningitidis and
N. gonorrhoeae have seen independent FetA activation via the Fur repressed AraC-like regulator
MpeR (241,247,248). The Zn transport systems, TdfH and TdfJ, are regulated similar to the iron
systems but belong to the Zur regulon and are under Zur regulation. Similar to Fur, when the
intracellular stores of Zn are high Zur monomers bind to Zn2+ and form dimers (249). These
dimers bind to Zur boxes on the DNA of Zur regulated genes and in the case of TdfH and TdfJ,
repress their transcription (242,250).
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IX.

Animal Models of Infection

N. gonorrhoeae is an obligate human pathogen and is highly adapted for survival inside
of a human host. This host adaptation has made it so that no animal models accurately mimic
human infection. This inadequacy is due to the number of host restricted proteins essential for
effective colonization and infection (251-253). Experimental genital tract infection has only been
successful in chimpanzees and estradiol-treated mice. The chimpanzee model of genital tract
infection is no longer available making the mouse model the only viable animal model for
evaluation of genital tract infections caused by N. gonorrhoeae (254,255). Treatment of mice
with 17β-Estradiol prevents overgrowth of commensal bacteria and extends the proestrus phase
of the mouse estrus cycle which is the optimal colonization phase (256,257). Recently, a human
transferrin transgenic mouse was generated and has been tested as an infection model with N.
meningitidis. While this model has shown promise, more studies are needed to determine its
ability to mimic human infection with both the gonococcus and meningococcus (258).
Additional insertions of human receptors critical to infections like carcinoembryonic antigen
cellular adhesion molecules (CEACAM), or Factor H may alleviate some of the difficulties
associated with animal models of this obligate human pathogen.
X.

Vaccination efforts

The continued rise in gonococcal infections, the dwindling number of clinically useful
antibiotics, and the lack of a protective immune response after infection highlights the need the
need for a new therapeutic gonococcal vaccine. These efforts have been hampered by the
antigenic variability, phase variation exhibited by many surface-exposed proteins of the
gonococcus, and the active suppression of an adaptive immune response (56,57). Further
complicating vaccine efforts is the ability of the gonococcus to prevent the deposition of
38

antibody on its surface. Gonococcal LOS that is decorated with sialic acid has been shown to
reduce the deposition of antibodies to porin proteins (259). The production of a conserved
protein RmpM acts as a decoy protein and prevents the deposition of bactericidal antibodies onto
gonococcal porin (260,261). An effective gonococcal vaccine will need to induce an immune
response within the mucosal tissue of the genital tract, which is devoid of organized lymphoid
tissue (262,263). New strategies at inducing mucosal immune responses through intranasal
vaccinations have shown promise at generating an immune response in the genital tract
(264,265).
The selection of an effective antigen is crucial for the development of an effective
gonococcal vaccine. Attempts to generate a pilin-based vaccine were unsuccessful even though
there was an abundant production of antibodies (266). Conserved portions of pilin are
immunosilent and thus, the immune response is driven by the highly variable portions of pilin,
which offer no cross-protection for strains expressing a different pilus (267). Since this attempt,
no other human trials of a gonococcal vaccine have been conducted; however, a recent study
found intravaginal vaccination with gonococcal OMVs administered with microencapsulated IL2 as adjuvant resulted in protection from gonococcal infection. This immunization method
resulted in cross-protection across numerous strains of N. gonorrhoeae and provided clear
evidence that with the correct immunogen, a protective immune response can be achieved
(268,269). A newly enticing vaccine antigen is the heptose-linked 2C7 epitope present within
gonococcal LOS (270). Despite the phase-variable nature of LOS, there is a strong selection for
the presence of this epitope during experimental infection. Passive delivery of 2C7 monoclonal
antibody protects against infection in mice and hexamerized 2C7 monoclonal antibody was
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bactericidal (271). A gonococcal vaccine using a peptide mimic of this epitope is currently under
development (272).
The conservation of TdTs and their limited antigenic variability has also added them to
the potential list of viable immunogens that could protect against gonococcal infection. The use
of TdTs is thought to provide the additional benefit of starving the gonococci of the essential
metal nutrients while also inducing cross-protective and bactericidal antibodies. Early studies
investigating the efficacy of the hTf system as an immunogen found that when a TbpA-Ctb
conjugate vaccine was administered intranasally to mice, there was an induction of crossprotective antibodies. A TbpB-Ctb conjugate vaccine was more immunogenic but its antibodies
were limited in their cross-protection (264). This discovery has led to the generation of new
“hybrid” antigens that allow extracellular-loop epitopes of TbpA to be presented in the context of
a TbpB scaffold. This is hypothesized to allow for maximal antibody induction that is seen with
TbpB based immunizations while maintaining the cross-reactive antibody production induced by
the TbpA based immunizations. Immunization with hybrid antigens of TbpA/TbpB in mice
resulted in the production of bactericidal antibodies and provided modest protection against
lower genital tract infection of N. gonorrhoeae (273). These studies highlight the promise of
TdTs as credible antigens for the protection against gonococcal disease and further studies
investigating other TdTs potential for protection are needed.
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Chapter 2: Methods and Materials

I. Bacterial growth and maintenance
Escherichia. coli strains used in this study were routinely cultured in Lauria Bertani broth
(274) supplemented with appropriate selection as follows: ampicillin at 100 μg/mL,
chloramphenicol at 34 μg/mL, and kanamycin at 50 μg/mL. Isopropyl β-D-1thiogalactopyranoside (IPTG) at 1 mM was used for the induction of complementation plasmids,
which allows for macA gene transcription under the control of the lac promoter. Gonococcal
strains were maintained on gonococcal base media (GCB, Difco) supplemented with Kellogg’s
supplementation (275) and 12 μM Fe(NO3)3. Iron stress was achieved by passage of isolated
gonococcal colonies onto GCB media supplemented with 5 μM deferoxamine (Desferal, Sigma
Aldrich). Lyophilized desferal was resuspended in sterile deionized water at a stock
concentration of 50 mM. For liquid culture and growth curve analysis, gonococcal isolates from
GCB-desferal plates were used to inoculate chemically-defined chelex-treated media
(CDM)(276). To achieve Zinc (Zn) restriction, cells previously grown on GCB media
supplemented with 12 μM Fe(NO3)3 were inoculated into CDM and incubated at 37oC with 5%
CO2 with shaking at 225 RPM for one mass doubling event, approximately 1-2 hour(s), before
addition of N,N,N',N'-tetrakis(2-pyridylmethyl)ethane-1,2-diamine (TPEN, Sigma Aldrich) to a
final concentration of 1 μM. TPEN stocks were generated by diluting TPEN in 100% ethanol at a
stock concentration of 1mM. Cultures were incubated at 37oC with 5% CO2 and shaking at 225
RPM for 3 hours before being standardized to 100,000 Klett unit μL for whole-cell lysates, or
15,000 Klett unit μL for blotting onto nitrocellulose membranes.
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II.

Small Molecule Inhibitors ELISA
Single colonies of gonococci grown on GCB containing 50 μM Desferal were swabbed

with a cotton-tipped swab and suspended in Phosphate buffered saline (PBS, 137 mM NaCl, 2.7
mM KCl, 10 mM N2HPO4, 176.35 μM K2PO4) to a final OD600 of 1.0. The resuspended culture
was added to a 96-well plate, coated in 0.01% poly-L-lysine overnight, and incubated at room
temperature for 1 hour. Gonococcal cultures were removed from the plate before a 1% casein
blocker in PBS blocker (ThermoFischer) was added. The plate incubated at room temperature for
one hour before the addition of small molecule inhibitors in the 1% casein blocker at a final
concentration of 100 μM was added to the wells. Unlabeled human transferrin at a concentration
of 2mg/mL (hTf, Sigma Aldrich) was used as a competitive inhibitor as a positive control of hTf
inhibition. The inhibitors were removed from the plate and 12 nM hTf conjugated to horseradish
peroxidase (hTf-HRP) was added to the wells. The plate was incubated with hTf-HRP for one
hour before being washed five times with PBS. The plate was developed with 3,3',5,5'tetramethylbenzidine (TMB, ThermoFischer) for 5-15 mins. 3 M sulfuric acid was added to stop
development before the plate was read on a Vmax microtiter plate reader at 420 nm.
III.

Testing Tf binding by TbpA mutants via ELISA
Iron-stressed gonococci grown overnight on GCB with 50 μM desferal was swabbed and

suspended into PBS at 1.0 O.D.600. Cultures were added to a Maxisorb 96-well plate
(ThermoFischer) coated in 0.01% poly-L-lysine and incubated at room temperature for 1 hour.
Cells were removed from the plate, and 3% bovine serum albumin (BSA) in PBS was added to
the wells as a blocker. Wells were washed three times with PBS before the addition of 12 nM
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HRP- hTf. Plates were incubated for 1 hour at room temp before being washed five times with
PBS. Plates were developed with TMB before 3M sulfuric acid was added to stop development.
Plates were read in a microtiter plate reader at 420nm.
IV.

Iron Saturation of hTf and bTf and Growth Premix Generation
Apo-bovine (bTf) and -human transferrin (hTf) was dissolved in initial buffer (100 mM

tris, 150 mM NaCl, 20 mM NaHCO3) at 10 mg/mL. Ferration solution (100 mM sodium citrate,
100 mM NaHCO3, 5 mM FeCl3- 6H20) was added to bTf or hTf in two-fold molar excess to
achieve desired saturation percentage. The proteins and ferration solution nutated at room
temperature for one hour. Solutions were added to pre-wet 10,000 Da cutoff Slide-A-Lyzer
dialysis cassettes (ThermoFisher) and dialyzed against dialysis buffer (40 mM Tris, 150 mM
NaCl, 20 mM NaHCO3) for 2 hours at room temperature before the buffer was swapped for fresh
buffer and dialyzed overnight at 4oC. Wild-type human calprotectin (WT-CP), site 1 knockout
(S1KO) human calprotectin, site 2 knockout human calprotectin (S2KO), double site knockout
human calprotectin (DKO), and murine calprotectin (MCP), supplied by Dr. Walter Chazin, was
diluted with PBS to 100 μM before being saturated with ZnSO4 at a 2:1 ratio of CP dimer to Zn
except for the S1KO and S2KO, which were mixed with a 4:1 ratio of CP dimer to Zn in order to
maintain equivalent levels of protein saturation. In order to restrict the growth of the gonococcus
to the desired iron and zinc sources, concentrated growth premixes were made and contained a
final concentration after dilution with culture of hTf at 7.5 μM, bTf at 2.5 μM, 10 μM HCP or
MCP and 5 μM TPEN. A 5 μM ZnSO4 free Zn premix that did not contain TPEN was used as a
positive control and a Zn devoid premix containing everything but a Zn source was used as a
negative control for Zn dependent gonococcal growth.
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V.

Generation of TbpA Double Mutants

E. coli containing the plasmids pVCU190 or pVCU191, which were originally generated by
Dr. Devin Cash, were grown overnight in LB with the selection of 34 μg/mL chloramphenicol.
Plasmids were prepped via Qiagen miniprep kit and subjected to SacI (New England Biolabs)
restriction endonuclease digestion overnight at 37oC. Linearized plasmid was precipitated in
100% ethanol and 120 mM sodium acetate overnight at -20oC. Digested plasmids were removed
from the freezer and centrifuged at max speed for 10 minutes, after which, the DNA pellet was
washed with 70% ethanol and subjected to another centrifugation at max speed for 10 minutes.
The DNA pellet was air-dried before being resuspended in sterile DNase- RNase free deionized
H2O. Piliated FA19 was streaked from freezer stock onto GCB plates and incubated as described
above. Piliated colonies were passed onto GCB plates and incubated overnight before being
suspended in 1 mL of GCB Alternative media (GCB containing 50 μM MgCl2, 130 μM CaCl2,
17.76 mM Glucose, 547.2 mM L-glutamine, 0.376uM thiamine pyrophosphate). In a separate
tube GCB alternative media, 10 μL of piliated FA19 cell suspension and 1 μg of linearized
plasmid DNA were mixed gently and incubated for 30 minutes at 37oC with 5% CO2 without
shaking. Fresh GCB alternative media was added to the wells of a 6-well cluster dish, and the
105 μLs of cell suspension was added to the cluster dish to a final volume of 900 μL. The plate
was incubated for 5 hours at 37oC with 5% CO2 before plating. The transformation reaction was
plated in 10 or 100 μL aliquots onto GCB media containing 1 μg/mL chloramphenicol and
incubated for two days at 37oC with 5% CO2. After two days, colonies were single colony
purified via serial passage onto GCB media plates supplemented with chloramphenicol at 1
ug/mL. A colony PCR for tbpA using primers oVCU 747 and oVCU748 was performed and the
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PCR produced was sent for sequencing to confirm the presence of the mutations in the
gonococcal chromosome. A PCR of tbpB using primers oVCU 750 and oVCU752 was
visualized using a 1.5% agarose ethidium bromide gel to confirm the presence or deletion of
tbpB.
VI.

macA deficient strain growth assays for gonococci heme sensitivity
FA19, macA::kan, pGCC3+::macAC, pGCC4+::macAC gonococcal strains were iron

starved overnight as previously described, and single colonies were used to inoculate CDM that
contained 1 mM IPTG. Strains were initially grown for approximately 2 hours or until one mass
doubling event. Cultures were standardized to 0.02 OD600 and plated in a 96-well microtiter
plate. Each well contained 2.5 μM apo-bovine transferrin as a chelator, and either 7.5 μM hTf or
heme as the sole iron source available to the gonococcus. Final heme concentrations of 25 μM,
15 μM, 10 μM and 5 μM were used as iron sources. Plates were incubated at 37oC with 5% CO2,
with shaking at 225 RPM, for 6 hours with hourly OD600 readings.
VII.

Isothermal Titration Calorimetry

Recombinant TdfH purified from E. coli inclusion bodies at a final concentration of 20 μM in
a PBS+ 0.05% n-Dodecyl-B-D-Maltoside (PBS-DDM) buffer was generously provided by Dr.
Nicholas Noinaj for the following isothermal calorimetry experiments. WT-Cp, S1KO, (ΔHis6),
S2KO (ΔHis3, Asp), and DKO (ΔHis6- ΔHis3, Asp) provided by Dr. Walter Chazin, was buffer
exchanged into PBS-DDM buffer via size exclusion chromatography. Relevant fractions were
pooled and concentrated to 200 μM. The reference cell and sample cell of the NanoITC
instrument were washed five times with PBS-DDM, before the addition of 300 μL of 20 μM
TdfH. Increasing concentrations of CP were incrementally titrated into TdfH over twenty
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injections and the changes in temperature were recorded. Analysis and fitting were performed via
origin through a multi-site fit.
VIII. CP dependent Growth Assays
FA19 was streaked from freezer stocks and patched onto full GCB plates before
inoculation into CDM. Cells were used to inoculate a trace-metal free sidearm flask containing
CDM to a density of 20 Klett units (KU). The cells were incubated at 37oC with 5% CO2 and 225
RPM until a Klett of 40 KU was reached (approximately 1 hour) after which, the culture was
back-diluted to 0.02 OD600 with fresh CDM. 100 μL of the back-diluted culture was added to a
96-well plate that was previously loaded with the various concentrated growth premixes. The
plate was incubated for 12 hours at 37oC with 5% CO2 and orbital shaking in a BioTek Cytation5
plate reader with absorbance readings taken every hour. Data were analyzed in GraphPad Prism
using a two-way ANOVA with post-hoc comparisons performed with Tukey’s multiple
comparisons test.
IX.

Whole-Cell Dot Blot Competition Assays
Gonococcal strains FA1090 (WT), MCV 661 (tdfH::Ω), MCV 662 (tdfJ::Ω) and MCV

936 (tdfJ::Ω, tdfH::Kan) were passaged on GCB media plates (Difco) two days before Zn
restricted liquid growth. Colonies from GCB plates were used to inoculate trace metal-free
flasks, and cultures were incubated at 37oC with 5% CO2 with shaking at 225 RPM for around 2
hours before the addition of a final concentration of 1 μM TPEN. Cultures incubated for
approximately 4 hours at 37oC with 5% CO2 before blotting onto a nitrocellulose membrane at a
standardized culture density of 30,000 Klett unit L. Blots containing gonococci were dried
overnight before blocking with 5% skim milk in low salt tris buffered saline (LS-TBS, 50 mM
Tris, 150 mM NaCl) for 1 hour. Blots were probed with 0.1 μM human calprotectin conjugated
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to horseradish peroxidase (HCP-HRP), HCP-HRP mixed with five- or ten-fold molar excess of
unlabeled HCP, or HCP-HRP combined with five- or ten-fold molar excess unlabeled MCP
competitor for 1 hour. Blots were washed with LS-TBS before being developed with DAB metal
substrate (Thermofischer) or Opti-4CN (Bio-Rad). The densitometries of scanned triplicated
blots were analyzed using Bio-Rad Image Lab.
X.

Total Calprotectin Binding Assay
Nitrocellulose membranes generated the same as the competition assay, were blocked

with 5% Skim milk in LS-TBS for 1 hour before being incubated with either 0.5 μM HCP or 0.5
μM MCP for 1 hour. Blots were washed with LS-TBS + 0.1% TWEEN 20, three times for 10
mins each, before being probed with a 1:100 dilution of αS100A9 antibody (ThermoFisher)
diluted in 5% skim milk blocker for 1 hour. Blots were washed, as before, in LS-TBS + 0.1%
TWEEN-20 and then goat α-mouse IgG conjugated to HRP secondary antibody (BioRad) at a
1:3000 dilution in 5% skim milk blocker was added to the blots for 1 hour. A final washing step
after secondary antibody incubation was performed, as the previous two, before development
with DAB C/N (ThermoFisher). Blots developed for approximately 10-15 mins before being
scanned for densitometry analysis.
XI.

Alignment of human and mouse S100A8 and S100A9 protein sequences

The sequences of human S100A8 (Accession number: AAH05928.1), S100A9 (Accession
number: AAH47681.1), mouse S100A8 (Accession number: NP_038678.1), and S100A9
(Accession number: NP_001268781.1) were pairwise aligned through Geneious using a Blossom
65 matrix. This alignment was then fed into ESPript 3.0 to produce the final alignment, which
includes the secondary structural elements taken from PDB ID 4GGF. The residues different
between human and mouse were then mapped to the surface of the human calprotectin structure
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using PyMOL (Schrödinger) and final figures prepared and assembled in Adobe Photoshop and
Illustrator.
Bacterial expression and purification of wild-type, mutant hCP, and mouse CP followed
previously described protocols (204,277) and was supplied and performed by Dr. Walter Chazin
from Vanderbilt University. The Zn binding site knock-out mutants (site 1- S1KO, site 2- S2KO,
both sites- TKO) have His-Asn substitutions for the 4 conserved His residues in site 1 and HisAsn substitutions for the 3 conserved His residues plus an Asp-Ser substitution for the conserved
Asp residue in site 2. Mouse S100A8 and S100A9 in pQE32 vectors, a kind gift from Professor
Claus Heizmann, were reengineered to remove the His tags. The protein was purified following
the protocol used for human CP. Briefly, plasmids were transformed in C41 E. coli cells
following standard procedures. For each protein, when the OD600 reached 0.6, cells were induced
at 37 °C by the addition of 1 mM IPTG and allowed to grow 4-12 hours post-induction. Cells
were harvested by centrifugation (6.5 krpm, 20 minutes, 4 °C) and re-suspended in Lysis Buffer
(50 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM PMSF, 0.5 % Triton X-100). Cells
were then sonicated (10 min, 50 watts, 5 seconds on/10 seconds off) and centrifuged at 20,000
rpm for 20 min. The supernatant was discarded and the pellet was re-suspended in Lysis Buffer
then sonicated and centrifuged as previously. The pellet was then re-suspended in 4 M
guanidinium-HCl, 50 mM Tris pH 8.0, 100 mM NaCl, and 10 mM BME. The solution was
centrifuged at 20,000 rpm for 20 min, then dialyzed against 20 mM Tris pH 8.0 and 10 mM
BME. The dialysis buffer was changed 3 times over the course of 12 hours. The solution was
centrifuged, filtered and loaded onto a SepharoseQ column (GE) (flow rate = 4 ml/min). After
loading, the column was washed with 3 CV Buffer A (20 mM Tris pH 8.0, 10 mM BME) and
eluted with a gradient (10 CV, 0→0.5 M) to Buffer B (20 mM Tris pH 8.0, 1 M NaCl, 10 mM
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BME). Relevant fractions were pooled, concentrated, and loaded onto a S75 column. Protein was
eluted with 1CV S75 Buffer (20 mM Tris pH 8.0, 100 mM NaCl, 10 mM BME). Relevant
fractions were pooled, flash frozen, and stored at -80 °C.
Recombinant TdfH was supplied by Dr. Nicholas Noinaj from Purdue University. The
TdfH-CP complex formation studies and TdfH homology modeling were also done at Purdue by
the Noinaj Lab. Briefly, the full-length tdfH gene (Neisseria gonorrhoeae; NGO0952) was
codon-optimized for expression in E. coli (Bio Basic). The tdfH gene was subcloned into the
pHIS2 plasmid using NcoI and XhoI restriction sites. Expression into inclusion bodies was
performed in BL21(DE3) cells, induced by addition of 0.2 mM isopropyl-D-1thiogalactopyranoside (IPTG) after growth to an OD600 of ~1.0, and induced at 37ºC for 3 hours.
The cells were then harvested and resuspended in 1x PBS pH 7.4 (10 mL per gram of cell paste)
supplemented with phenylmethylsulfonyl fluoride (200 M final concentration) and DNaseI (10
g/mL final concentration). The cell suspension was lysed by three passes through an Emulsiflex
C3 (Avestin) at 15,000 psi. The lysate was centrifuged at 7,000 x g for 20 min at 4 ºC, and the
pellet washed three times with 1x PBS supplemented with 1% triton X-100 and 5 mM
(Ethylenediaminetetraacetic acid) EDTA pH 7.4, one time with 3 M urea in 1x PBS, and two
times with 1x PBS with 5 mM EDTA pH 7.4 using a dounce homogenizer.
Washed inclusion bodies were resuspended to 5-10 mg/ml in 8M urea containing 2.5 mM
-mercaptoethanol (BME) in a dounce homogenizer and supplemented with 0.5% sarkosyl. This
was mixed for 15 min at room temperature and then centrifuged for 15 min at 32,000 x g. The
supernatant was then diluted 60% in refolding buffer [20 mM Tris-HCl pH 8.0, 200 mM NaCl,
10% glycerol and 0.17% n-Dodecyl-B-D-Maltoside (DDM)] and dialyzed overnight at 4 ºC
against a 20x volume of 1x PBS pH 7.4.
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The dialyzed sample was centrifuged at 32,000 x g for 15 mins at 4 ºC and further purified
using a linear gradient (25 - 300 mM imidazole) with a Ni-NTA column attached to an AKTA
Purifier (GE Healthcare) in Buffer A (1x PBS pH 7.4 buffer, 0.05% DDM) and Buffer B (1x
PBS pH 7.4 buffer, 0.05% DDM, 1 M imidazole). Peak fractions were verified by SDS-PAGE
and the purest fractions were combined and treated with TEV protease at 4 ºC overnight in
dialysis into 1x PBS. The sample was then passed over a second Ni-NTA column and the flowthrough concentrated and further purified using a Superdex 200 Increase 10/300 GL column (GE
Healthcare) in 1x PBS pH 7.4 supplemented with 0.05% DDM.
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Table 1.1
Strain
FA1090

Gonococcal Strains and Plasmids
Genotype

Reference

WT lbpBΔ

(278)

FA19

WT

(279)

FA6905

FA19 tbpBΔ

(252)

FA6815

FA19 tbpB::Ω

(215)

MCV 661

FA1090 tdfH::Kan

(227)

MCV 662

FA1090 tdfJ::Kan

(280)

MCV 936

FA1090 tdfJ::Ω, tdfH::Kan

(231)

MCV 168

FA19 tbpBΔ, TbpA K359R

(281)

MCV 210

FA19 tbpBΔ, TbpA D251A

This Study

MCV 211

FA19 tbpBΔ, D251A/ K359R

This Study

F–, endA1, supE44, thi-1, recA1, relA1, gyrA96,

Stellar Top10

phoA, Φ80d lacZΔ M15, Δ (lacZYA - argF) U169,

Takara Clonetech

Δ (mrr - hsdRMS - mcrBC), ΔmcrA, λ–

Plasmids

Genotype

Reference

pVCU 190

pUNCH 755 TbpA D251A

This Study

pVCU 191

pUNCH 755 D251A/ K359R

This Study

pUNCH 1304

pCRII hemH::CAT

(282)
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Chapter 3: Affinity and Species Specificity of the Interaction Between TdfH of Neisseria
gonorrhoeae and Its Ligand, Human Calprotectin

Introduction
Neisseria gonorrhoeae is responsible for the sexually-transmitted infection gonorrhea
and has resulted in a steady rise in infections worldwide over the last decade (283,284). In 2018
alone, the number of reported gonococcal infections reached over 500,000 in the United States
(283). Increasing antimicrobial resistance among recently-isolated strains has complicated the
treatment of this infection (60,285). The accumulation of antimicrobial resistance has left
clinicians with few remaining therapies. The current CDC-recommended treatment is dual
therapy with ceftriaxone plus azithromycin (60). A recent case study in the United Kingdom
reported a patient infected by a gonococcal strain exhibiting high levels of resistance to both
drugs in the dual therapy, marking the beginning of an era where there may be no effective
treatments for gonococcal infections (61,286). The lack of protective immunity against N.
gonorrhoeae after infections, coupled with the closing window of treatments available,
highlights the need for new therapeutics or ideally vaccine interventions that would prevent
gonococcal diseases.
Previously, four major attempts at generating a gonococcal vaccine have all failed their
respective clinical trials likely due to the antigenic diversity of N. gonorrhoeae surface structures
(287) . Whole cell, partial autolyzed cell, porin, and pilus based vaccines were unable to induce a
cross protective immune response and were unable to protect individuals from future
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gonococcal infections (266,288-290). The pilus based vaccine attempt was one of the first
attempts at gonococcal vaccination and demonstrates the problems with generating a cross
protective immune response (266). Gonococcal pilus genes undergo high frequency antigenic
variation, which results in a new pilin variant in every 102-103 cells (70,71). The pilin-based
vaccine was capable of stimulating a robust immune response and showed protection, but the
protection included preventing infections from cells expressing only the exact same pilus protein
(266). The number of pilin protein variants that can be generated effectively removed the use of
pilin as a viable vaccine candidate, and is a common issue among many gonococcal surface
proteins like those used in the whole cell, porin, and partially autolyzed vaccines. The sheer
antigenic diversity of gonococcal surface proteins necessitates the need to search for more
suitable vaccine candidates. It is our belief that the incorporation of conserved outer-membrane
proteins which exhibit minimal antigenic variation or phase variation, and are immunogenic, will
provide the best chance of success for a future protective-gonococcal vaccine.
In order to inhibit microbial invaders from multiplying, mammalian hosts deploy
“nutritional immunity” as a means to restrict metals via the production of metal-binding proteins
(129). This protective mechanism was first described in the context of iron deprivation but
extended to other transition metals as well (129,291). Metal sequestration, as well as tight control
of metal metabolism, leaves the human body depleted for free metals. N. gonorrhoeae is highly
effective at subverting host nutritional immunity by hijacking human metal-binding proteins and
using the metal cargo for growth and survival (129,131,209,292-294). This “metal piracy” is
accomplished via a family of outer-membrane transporters, known as TonB-dependent
transporters (TdTs). These transporters depend on the TonB-ExbB-ExbD complex of proteins to
harness the energy generated by the proton motive force across the inner membrane (207,295).
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The gonococcus can utilize iron-bound to human transferrin and lactoferrin as metal sources and
has recently been shown to utilize S100A7 for Zn-dependent growth (209,230,296). TdTs are
highly conserved, demonstrate limited antigenic variation and, in the case of TbpA, promote the
generation of cross protective antibodies. Therefore, TdTs have been the subject of recent
attempts at the development of a gonococcal vaccine (273).
The gonococcal genome encodes eight known TdTs, with five of these transporters,
TbpA, LbpA, HpuB, TdfJ, and TdfH, binding to a known host ligand (226,295). Iron acquisition
via transferrin is accomplished through TbpA, which demonstrates a species specificity for only
human transferrin (252,296). Similarly, Zn acquisition through S100A7 is achieved via the
production of the gonococcal transporter TdfJ and exhibits a similar species restriction for ligand
binding (230). N. gonorrhoeae has also been shown to utilize human calprotectin (hCP,
composed of a heterodimer of S100A8 and S100A9) for survival in neutrophil extracellular traps
[NETs]) (231).
Calprotectin (CP) is one of its most abundant cytosolic proteins found within neutrophils
and can also be found within the primary and secondary neutrophilic granules (297). When
neutrophils undergo the process of NET formation, NETosis, CP is secreted into the extracellular
environment and contributes to the antimicrobial activity of NETs through its metal sequestering
properties (298-300). The metal sequestration exhibited by CP is attributed to its two metalbinding sites, which are found on opposite sides of the dimer interface. These sites are defined by
the residues that are responsible for metal chelation. The first site, known as site 1, is composed
of 6 histidine residues, which is different than the metal coordinating residues found within other
S100 proteins (301). Site 1, and its unique makeup, allows for the flexibility of binding more
than just Zn (301). The second site, known as site 2 has the canonical set of residues found
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within other S100 proteins, three histidines and an aspartic acid residue. Unlike site 1, site 2 only
has the ability to bind to Zn (205). Zn piracy from CP has been described as being TdfHdependent in N. gonorrhoeae (231,302).
TdfH is highly conserved among the pathogenic Neisseria species making it a promising
candidate for vaccine or drug design (302). In our studies here, as is true for other protein-protein
interactions in the pathogenic Neisseria, the TdfH-CP interaction is demonstrated to be human
restricted. Zn-loaded mouse calprotectin was not capable of supporting the growth of the
gonococcus in a TdfH-dependent manner. Using isothermal calorimetry, the binding of TdfH
with hCP fit a two-state model characterized by low and high-affinity binding with micromolar
and nanomolar affinities, respectively. The growth deficiency of N. gonorrhoeae with the S1KO
hCP point mutant, which is unable to bind Zn at the non-canonical metal-binding site, indicates
that metal scavenging may occur optimally at Site 1. We find that TdfH is necessary and
sufficient for hCP binding, resulting in Zn acquisition directly from hCP. Our studies provide
molecular insight into the interaction of TdfH with hCP and allow us to form a working
structural model for the TdfH/hCP complex in the piracy of Zn. This insight provides the
blueprint for further investigations of the vaccine potential of TdfH and new therapeutics that
disrupt the TdfH-hCP interaction.
I.

Results

A. N. gonorrhoeae growth is not supported by mCP and preferentially binds hCP
Jean et al. (231) demonstrated that the gonococcus could use CP in a TdfH-dependent
fashion, resulting in Zn accumulation. Furthermore, this study demonstrated an in vivo relevance
for the production of TdfH in that production of this transporter enabled the gonococcus to better
survive killing by neutrophil extracellular traps (NETs)(231). While Jean et al. demonstrated a
direct interaction between CP and whole, TdfH-producing gonococcal cells, direct protein55

protein interactions were not previously shown, nor was the mechanism or affinity of the
interactions measured. In the current study, we investigated whether the interactions between
TdfH and CP were species-specific. Previously-studied gonococcal TdTs bind and acquire
metals specifically from the human forms of their ligands (230,252,303). To test if this was also
true for TdfH, FA19 cells grown in CDM were supplemented with ~25% saturated mCP as the
sole Zn source according to previously described methods (230,231). Compared to cultures
grown with 5 μM free Zn, cells that were grown with 25% saturated mouse calprotectin (MCP)
had significantly impaired growth (Figure 3.1). The growth of FA19 with mCP as the sole Zn
source was not statistically different from the no Zn control.
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Figure 3.1

Growth of Neisseria gonorrhoeae when mCP is supplied as the sole Zn source.
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Figure 3.1

Growth of Neisseria gonorrhoeae when mCP is supplied as the sole Zn source.

Gonococcal cells were allowed to double in CDM, then were diluted to an OD600 of ~0.02
and transferred to a 96-well microtiter plate containing concentrated growth premixes. Cells
supplemented with mCP as the sole Zn source (red inverted triangles) were significantly
deficient in their ability to support growth of the gonococcus beginning at 6 hours (p<0.05= *,
p<0.01= **) compared to the free Zn positive control (black open circles) and hCP (blue
triangles). There was no significant difference (ns) in growth between the no Zn treatment and
cells supplemented with mCP as the sole Zn source. Significance was determined via a two-way
ANOVA with Tukey post-test. Error bars represent standard error of the mean (SEM) of three
independent experiments performed in technical triplicate.
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TdfH has been implicated as being necessary for binding to hCP in whole gonococcal
cells (231). In an attempt to define the specific interactions between TdfH and CP, a competition
assay was developed to assess whether TdfH preferentially interacts with hCP or if mCP was
also able to compete for binding to TdfH. Whole cells of the following strains were immobilized
onto a nitrocellulose membrane: FA1090 (WT), MCV661 (TdfH knockout), MCV662 (TdfJ
knockout), and MCV936 (TdfH/TdfJ knockout) as described in Table 1. Membrane-bound cells
were blocked and probed with hCP-HRP alone, with hCP-HRP mixed plus 5- or 10-fold molar
excess hCP or with hCP-HRP plus 5- or 10-fold molar excess mCP. The first row containing the
WT strain FA1090 showed a decrease in the HRP signal in the presence of an unlabeled hCP
competitor (Figure 3.2A, second and third columns). mCP competitor at either concentration
did not reduce the HRP development of the blots (Figure 3.2A, last two columns). The second
row, which contained the TdfH KO strain MCV661, showed background levels of HRP
development (Figure 3.2A). The third row of the blot contained a TdfJ KO strain also exhibited
a decrease in development when probed with hCP competitor (Figure 3.2A, second and third
columns), but demonstrated no reduction in development when mCP was used as a competitor
(Figure 3.2A, last two columns). The fourth and final row of the blot contained the TdfH and
TdfJ double knockout (DKO) strain MCV 936, which exhibited background levels of
development when probed with either hCP or mCP competitors (Figure 3.2A). Densitometry
scans of biological triplicate competition assays were used to quantify the reduction in hCP-HRP
binding to the cell surface (Figure 3.2B). When blots were probed with either 5- or 10-fold
molar excess hCP competitor, a significant reduction in HRP signal can be observed (p<0.05); no
significant reduction in signal was seen when mCP was added as a competitor.
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Figure 3.2

hCP and mCP competition dot blot assay.
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Figure 3.2

hCP and mCP competition dot blot assay

(A) Representative image of competitive CP binding assays. N. gonorrhoeae strain FA1090
(WT), MCV661 (TdfH KO), MCV662 (TdfJ KO) and MCV936 (DKO) were grown under Znrestricted conditions and applied to nitrocellulose membrane at a standardized density.
Membranes were probed with either 0.1 μM hCP- HRP alone or a mixture of 0.1 μM hCP-HRP
combined with 0.5 μM or 10 μM hCP or mCP unlabeled competitor. (B) Densitometry analysis
of biological triplicate sets of dot blots. Densitometry analysis was accomplished using BioRad’s Image Lab software. Significance was calculated via an unpaired Student’s t-tests with
WT-No Comp treatment used for comparison with biological triplicates done in technical
triplicate (error bars calculated via the standard error of the mean (SEM), p<0.05 = *)
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The hCP-HRP may have a higher affinity for binding to TdfH than mCP does and could,
therefore, outcompete mCP for binding to TdfH. To test this hypothesis, the binding of both hCP
and mCP was assayed alone independently in total CP binding assays (Figure 3.3A). A control
western blot using the α-S100A9 monoclonal antibody was performed to ensure both hCP and
mCP were detectable prior to performing the total calprotectin binding experiments. Membranes
blotted with the same strains as in Figure 3.2A were probed with either 0.5 μM hCP or 0.5 μM
mCP followed by an α-S100A9 monoclonal antibody cross-reactive for hCP and mCP. The blots
were developed with an α-rabbit IgG-HRP secondary. Similar to the results from the competition
assay, the WT and TdfJ KO, which both express TdfH, bound hCP but not mCP. Likewise, cells
lacking TdfH (the TdfH KO and the double KO) do not bind either of the calprotectins.
Quantitative measures of these blots were determined through densitometry (Figure 3.3B),
which showed significantly reduced mCP binding (by ~60% or more) in all strains compared to
hCP binding to WT. Further, all mutant strains except the TdfJ KO showed more than 60%
reduction in hCP binding. The inability of mCP to interact with whole gonococci, both in a
competitive format or alone coupled with Zn-saturated mCP not supporting gonococcal growth
strongly suggests that mCP is not a natural ligand for TdfH. Further the lack of interaction
between TdfH and mCP suggests that TdfH may have a human ligand restriction for binding and
Zn-piracy.
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Figure 3.3

hCP and mCP binding to the gonococcal surface.

63

Figure 3.3

hCP and mCP binding to the gonococcal surface.

(A) Representative image of direct CP binding assays. N. gonorrhoeae strain FA1090
(WT), MCV661 (TdfH KO), MCV662 (TdfJ KO) and MCV936 (DKO) were immobilized onto
nitrocellulose were probed with 0.5 μM hCP or 0.5 μM mCP. Calprotectin bound to the surface
of cells was detected with an α-S100A9 monoclonal antibody followed by detection using an αmouse IgG conjugated to HRP. (B) Densitometry of three independent biological replicates
performed in technical triplicate. Densitometry of scanned blots demonstrated a significant
reduction in the binding of mCP to affixed gonococci compared to the binding of hCP to the WT
strain. Significance was calculated by an unpaired Student’s t-test with comparisons made to
FA1090 probed with mCP. Error bars represent SEM with p<0.01 = **.
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B. TdfH and hCP forms complexes detected via SEC
To determine whether we could recapitulate the TdfH interaction with hCP in vitro, we
codon-optimized the gene sequence for TdfH and subcloned the gene into the pHIS2 and
pET20b (modified with an N-terminal 10X His tag and TEV protease site) vectors for expression
in E. coli. While the native expression (pET20b vector) was only barely observable by Western
blot analysis, we were able to express TdfH into inclusion bodies (pHIS2 vector) with high
yields. We refolded and purified TdfH using a Ni-NTA column and did a final purification using
size-exclusion chromatography into 1x PBS with 0.05% DDM. The sample was then mixed at a
ratio of 1:2 with each hCP and mCP, incubated for at least one hour, and then separated again
using size-exclusion chromatography into 1x PBS with 0.05% DDM. Similarly, control samples
of hCP and mCP were also analyzed for comparison. As shown in Figure 3.4A, we observed a
clear shift in hCP such that it co-elutes with TdfH, as visualized by SDS-PAGE analysis (Figure
3.4B). Conversely, no observable shift was detected with mCP (Figure 3.4C and 3.4D), even
after TCA precipitation of the samples to boost the low signal from mCP (Figure 3.4E). The
lack of a native membrane presentation of TdfH had no effect on the interaction between TdfH
and hCP. These results demonstrate that TdfH alone is responsible for the ability of N.
gonorrhoeae to distinguish between human and mouse CP and interact with human calprotectin
and.
C. hCP and TdfH interact with nanomolar affinity
One of the signature symptoms of gonococcal infection is the influx of neutrophils into
the site of infection driven by localized inflammation (304-306). Human neutrophils can undergo
a process of NETosis, releasing their intracellular and granular contents, including the highly
abundant cytosolic protein HCP (299,300,307). hCP has been documented to reach
concentrations as high as 1 mg/mL in inflamed tissues.
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Figure 3.4

Recombinant TdfH and calprotectin complex formation.
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Figure 3.4

Recombinant TdfH and calprotectin complex formation.

(A) Recombinant TdfH (blue), hCP (black), or TdfH incubated with hCP (red) were run
over a Superdex 200 column. Fractions collected, which are highlighted in grey, were run on a
15% SDS-PAGE gel. (B) 15% SDS-PAGE of TdfH alone, hCP alone, TdfH and mCP incubated
together and collected fractions. TdfH incubation with hCP resulted in co-elution in fractions
collected from SEC (dotted box) indicating the formation of a TdfH-hCP complex. (C)
Recombinant TdfH (red), mCP (purple), and TdfH incubated with mCP (blue) were run over a
Superdex 200 column. Fractions collected for SDS-PAGE analysis are highlighted in grey. (D)
15% SDS-PAGE gel of TdfH, mCP and collected fractions of TdfH incubated with mCP. TdfH
and mCP that had been incubated together independently eluted during SEC (dotted box). (E)
Two fractions that eluted only TdfH (purple and green arrow) and only mCP (orange and
blue arrow) were chosen for TCA precipitation to see if any amount of TdfH or mCP eluted
together. TCA precipitated contained only TdfH (purple and green) or mCP (orange and blue)
indicating the inability for TdfH-mCP complexes to form.
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We therefore investigated whether this high abundance neutrophil protein, found on
inflamed mucosal membranes, interacted with TdfH with high affinity. Isothermal titration
calorimetry (ITC) was used to determine the binding affinity of the interaction between TdfH
and hCP and duplicate experiments were performed to ensure that the data was reproducible.
Prior to injections of CP into TdfH, hCP and mCP were titrated into a sample cell containing just
buffer. These injections determined that hCP and mCP had a minimal heat release when injected
into buffer alone, and thus our titrations were optimized to reach a phase of static heat release
upon ligand saturation rather than no heat release which is typical of ITC isotherms. Here, 300
L of 20 μM of TdfH was loaded into the sample well of a Nano ITC microcalorimeter, and 2.5
L of 200 μM of hCP was incrementally titrated into the TdfH over 20 injections. Using the
NanoAnalyze software package, the isotherm of the TdfH and hCP ITC experiment (Figure
3.5A) was found to best fit a two-state model, allowing us to determine the binding parameters
for the interaction. Two distinct binding profiles were observed indicating multiple modes of
interaction in a two-state model. The first was a high-affinity interaction with the affinity
calculated to be 4.0 nM (Table 2). The second binding profile was a low-affinity interaction with
an affinity 35 μM. The lack of growth support, competition, and complex formation with TdfH
by mCP led us to question if mCP had any detectable interaction with TdfH. Similar to the ITC
of hCP, a titration of mCP was performed and analyzed using a two-state model (Figure 3.5B).
Similar to the addition of hCP, the titration of mCP into the TdfH containing cell yielded two
affinities, with the highest affinity determined to be 0.72 μM and the lowest as 51 μM (Table 2).
However, unlike the hCP interaction there was less overall heat release (kcal/mol) when mCP
was added to TdfH indicating that there was minimal interaction between mCP and TdfH. The
ITC experiments determined that TdfH binds to hCP with high affinity, while the interaction of
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TdfH and mCP is much lower. The ITC experiments also found that there was a second unique
binding interaction between TdfH and CP. The two-state interactions suggest that TdfH may
bind to CP at two unique sites where one of those sites is the preferred location for Zn metal
piracy, or TdfH could bind to CP in two stages.
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Figure 3.5

Isothermal titration calorimetry of hCP and mCP with TdfH
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Figure 3.5

Isothermal titration calorimetry of hCP and mCP with TdfH.

Calprotectin was titrated into TdfH over 20 injections. ITC experiments were done in
duplicate to confirm reproducibility of the isotherm fits. (A) Using NanoAnalyze, the isotherm of
the hCP injections best fit a multi-site model and resulted in high and low affinities of 4.0 nM
and 35 μM (bottom). When hCP was incrementally titrated into the TdfH containing sample
well, a robust heat release was detected (top). (B) The mCP titration isotherm had dramatically
reduced kcal/mol heat release compared to hCP (top). The mCP isotherm best fits a two-state
model with calculated high and low affinities of 0.72 M and 51 μM (bottom).
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Best-fit Multi-site
Mode
l Ka1
-1

(M )

Multi-site

2.5 x 108 ± 4.7 x
107

Ka2 (M-1) 2.8 x 104 ± 5.9 x
103
0.55 ± 0.017
n1

Multi-site

Multi-site

Independent

1.4 x 106 ± 8.6 x 105 ± 3.8 x
3.4 x 106
106

1.5 x 107 ± 1.5 x 107

-

1.5 x 104 ± 9.2 x
104
1.3 ± 0.208

1.7x 104 ± 1.8 x 104

-

0.40 ± 0.012

0.67 ± 0.12

2.1 ± 6.4

8.8 ± 1.0

-

n2

1.2 ± 0.5

2.0 x 104 ±
5.6 x 104
0.28 ±
0.063
7.8 ± 2.2

ΔH1

-26 ± 1.7

-50 ± 19

3.2 ± 17

-4.6 ± 5.9

-25 ± 5.04

ΔH2

-32 ± 4.7

50 ± 7.4

50 ± 20

25 ± 13

-

(kcal/mol)
KD1 (M)

4.0 x 10-9

7.3 x 10-7

1.2 x 10-6

6.6 x 10-8

1.3 x 10-5 ± 3.8 x
10-6

-50

-140

38

17

-62

5.1 x 10-5

6.8 x 10-5

6.0 x 10-5

-

190

190

101

-

(kcal/mol)

ΔS1
(cal/mol·K)

KD2 (M) 3.5 x 10-5
ΔS2

-81

(cal/mol·K)

Table 2

Summary of isothermal titration calorimetry parameters
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D. hCP and mCP share limited sequence identity
The ability for TdfH to differentiate between the human and mouse forms of CP led us to
investigate the similarity between the amino acid sequences of the proteins. CP is an obligate
heterodimer made up of S100A8 and S100A9, and contains two metal-binding sites of interest
which have been previously identified as site 1 and site 2 (Figure 3.6) (308). The sequences for
human S100A8 (AAH05928.1) and S100A9 (AAH47681.1) were aligned to mouse S100A8
(NP_038678.1) and S100A9 (NP_001268781.1) using Geneious software and then visualized
using ESPript 3 (Figure 6B) (194,309). Human and mouse S100A8 shared 58% sequence
identity and 83% similarity, while the S100A9 proteins shared 58% sequence identity and 74%
similarity. Mapping the divergent residues to the surface of the hCP structure (PDB ID 4GGF)
reveals that most of the diversity is found at the ends of the CP structure in proximity to the site 1
and site 2 metal-binding sites (Figure 3.6C).
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Figure 3.6

Pairwise alignment of human and mouse S100A8 and S100A9 proteins
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Figure 3.6

Pairwise alignment of human and mouse S100A8 and S100A9 proteins
(A) The structure of human calprotectin (PDB ID 4GGF) in complex with

manganese (red spheres). The locations of metal-binding sites 1 and 2 are indicated in stick. (B)
A sequence alignment of human and mouse calprotectin subunits, with mapped secondary
structural elements. Sequences for human (AAH05928.1) and mouse (NP_038678.1) S100A8
proteins were aligned through Geneious with a BLOSUM 65 matrix. The S100A8 sequences
share 58% identity and 83% sequence similarity. Mouse S100A8 is 89 amino acids whereas
human S100A8 is 93 amino acids in length. Sequences for human (AAH47681.1) and mouse
(NP_001268781.1) S100A9 proteins were aligned sharing 58% identity and 74% sequence
similarity. Mouse S100A8 is 113 amino acids whereas human S100A8 is 114 amino acids in
length. Residues making up the site 1 metal-binding site are indicated by the magenta arrows
while those making up the site 2 metal-binding site are indicated by cyan arrows. (C) Based on
the sequence alignment in panel B, residues that are different between human and mouse
calprotectin were mapped to the surface of the human calprotectin structure (highlighted in blue;
gray indicates identical residues). The most divergent regions between the two are found along
the ends of the calprotectin structures close to the site 1 and site 2 metal-binding sites (indicated
by the dashed circles).
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E. The S1KO hCP is unable to support the growth of N. gonorrhoeae
The antimicrobial properties of HCP have been found to negatively affect a variety of
microorganisms, including Staphylococcus aureus and Candida albicans (202,203,277). This
antimicrobial effect has been attributed to the metal sequestration properties of the protein. hCP
has two sites available for metal sequestration, with site 1 capable of coordinating a Zn or Mn
ion, and site 2 coordinating a Zn ion only (204). To determine whether TdfH was capable of Zn
acquisition from both metal-coordinating sites of hCP, FA19 was grown with the following as
the sole Zn source: WT hCP, site 1 knockout CP (S1KO), site 2 knockout CP (S2KO), and a
total knockout CP which binds no metals (TKO), which were all purified and supplied by Dr.
Walter Chazin from Vanderbilt University (Figure 3.7). The S1KO has Asn substitutions at the
four His residues responsible for transition metal binding. The S2KO has Asn substitutions at the
three His residues and a Ser substitution at the Asp residue responsible for transition metal
binding. The TKO has both of the above mutations. Calprotectin added to the concentrated
growth premixes was previously loaded with ZnSO4 to achieve 25% saturation (230,231). Cells
that were grown in the presence of the S1KO as the sole Zn source demonstrated limited growth,
similar to that of the no Zn negative control. Similarly, gonococci grown in the presence of the
TKO grew in a manner that was not significantly different from the no Zn control. Gonococci
grown with S2KO as the sole Zn source, by contrast, demonstrated growth patterns that were not
significantly different from cells grown using the WT hCP. Free Zn, WT hCP, and the S2KO CP
all supported growth that was significantly higher when compared to the no Zn, S1KO and TKO
HCP controls. No significant differences were noted in the growth patterns when gonococci were
provided free Zn, WT hCP, or S2KO as sole Zn sources. The lack of growth support detected
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with the S1KO provides strong evidence that the interaction between TdfH and hCP is located
predominantly around site 1 and is potentially the primary location of Zn piracy from hCP by the
gonococcus.
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Figure 3.7

Growth of N. gonorrhoeae when hCP Zn-site knockouts are used as the sole
Zn source.
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Figure 3.7

Growth of N. gonorrhoeae when hCP Zn-site knockouts are used as the sole
Zn source.

Gonococcal strain FA19 was grown with concentrated premixes containing hCP and hCP
site knockouts as the sole Zn source. hCP was saturated to 25% with ZnSO4 and dialyzed
overnight against their native buffer containing chelex-100 resin to remove any unbound residual
Zn. FA19 that had been grown with 5 μM free Zn (black open circles), 10 μM WT-hCP (red
triangles) and 10 μM S2KO (blue diamonds) had significantly increased growth compared to the
No Zn treatment (back open boxes) and had no significant difference in growth when compared
to each other. The free Zn, WT, and S2KO also demonstrated a significant growth increase
compared to the S1KO (orange inverted triangles) and TKO (green circles). The S1KO and TKO
growth were not significantly different from the growth of our no Zn negative control which
displayed minimal growth over the 9-hour incubation. Statistics of biological triplicate
performed in technical triplicate were done via a two-way ANOVA with a Tukey post-test.
p<0.05= *. Error bars represent standard error of the mean (SEM).
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F. TdfH interaction with hCP depends on the sequence at each Zn binding-site
ITC was employed in order to examine the role that each separate metal-binding site of
hCP plays in the interaction with TdfH. TdfH was mixed with either S1KO or S2KO over 20
injections as previously described in this study. Isotherms for the S1KO and S2KO were
analyzed with NanoAnalyze and the best fit was to a two-state model. Similar to the wild-type
protein, both the S1KO and the S2KO mutated proteins demonstrated two distinct binding
affinities (S1KO: 1.2 M and 68 μM [Figure 3.8A]; and S2KO: 66 nM and 68 M [Figure
3.8B]). Taken together, these results suggest that knocking out site 1 has a more negative effect
on HCP binding than does knocking out site 2. Further, we also titrated in hCP-TKO with TdfH
(Figure 3.8C). Interestingly, analysis of the TKO data showed a shift from a multi-site model to
an independent model with a single, low-affinity binding of 13 M. These data align well with
the cell-based studies presented in the previous section where we demonstrated that site 1
appears to be more important for supporting growth of the gonococcus (Figure 3.7).
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Figure 3.8

Isothermal titration calorimetry of S1KO, S2KO, and TKO hCP with TdfH
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Figure 3.8

Isothermal titration calorimetry of S1KO, S2KO, and TKO hCP with TdfH

The S1KO HCP (A) and S2KO HCP (B) were each titrated into TdfH over 20 injections.
Isotherms for both the S1KO and S2KO titrations best fit with a multi-site model using
NanoAnalyze. A. Injection of S1KO into TdfH was calculated to have high and low affinities of
1.2 M and 68 μM. B. Injection of S2KO into TdfH was calculated to have high and low
affinities of 66 nM and 68 μM. C. The isotherm for the TKO titrations best fit an individual site
model. Injection of TKO into TdfH was calculated to have an affinity of 13 μM. The S1KO,
S2KO, and TKO isotherms all had dramatically reduced kcal/mol heat release compared to hCP.
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Figure 3.9

Homology model of TdfH and insight into the interaction with human
calprotectin
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Figure 3.9

Homology model of TdfH and insight into the interaction with human
calprotectin.

(A) The membrane topological map of TdfH based on homology modeling using
sequence and structural alignments of the closest homologs. (B) A superposition of the TdfH
models from the molecular dynamics (MD) simulations at 0, 50, and 100 nanoseconds (gray,
gold, and red, respectively), showing a stable membrane barrel domain throughout the simulation
with little variability. (C) A plot from the MD simulations of the average RMSD of TdfH
residues within the barrel only versus all residues. The barrel domain (as well as the plug
domain) is significantly more stable than the rest of the protein which consists mostly of
elongated extracellular loops. (D) Electrostatic surface potential comparison of the ZnuD
structure (PDB ID 4RDR) with the TdfH homology model. Similar characteristics were
observed, including the electropositive belt (dashed ovals), the membrane belt (dashed
rectangles), and the electronegative surface loops (bottom, dashed circles). (E) Electrostatic
surface properties of human calprotectin (PDB ID 4GGF). Both site 1 and site 2 regions were
observed to be strongly electronegative, while the divergent regions noted in Figure 6 in
proximity to site 1 and site 2 were significantly less charged by comparison. A nearly identical
observation was seen with a model of mouse calprotectin (data not shown), suggesting that
electrostatics alone is not responsible for binding to TdfH.
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Discussion
Neisseria gonorrhoeae is a pathogen that is uniquely adapted for survival inside the
human body. An evolutionary study examining primate orthologs of transferrin found that
transferrin, specifically the C lobe that interacts with neisserial TbpA, has undergone a rapid
evolution, driven by positive selection by bacterial TbpA proteins (310). This TbpA-driven
transferrin evolution emphasizes the impact that gonococcal iron piracy proteins have on their
host (311). While much of nutritional immunity was previously focused on the sequestration of
iron, the importance of controlling the concentrations of other free transition metals, such as Zn,
Mn, and Cu, has recently been recognized (203,291,308,312-314). The S100 family of proteins,
all of which are EF-hand calcium-binding proteins, has been implicated as one of the major
transition metal chelators in inflamed tissues (193,194). Two TdTs produced broadly by the
pathogenic Neisseria have been found to utilize select S100 proteins as sole metal sources in
order to overcome host nutritional immunity. The TdfH homolog, renamed CbpA, was
demonstrated to enable interaction between Neisseria meningitidis and CP (302). Jean et al.
subsequently demonstrated that N. gonorrhoeae could grow on CP and internalize Zn from CP in
a TdfH-dependent manner and that production of TdfH enhanced gonococcal survival in
neutrophil NETs (231). The TdfJ homolog, renamed ZnuD, was purified from N. meningitidis
and crystalized. The structure of this TdfJ homolog bound directly to Zn and thus was described
as a Zn transporter (229,315). Subsequently, Maurakis et al. determined that TdfJ enabled
growth and Zn uptake from an S100 protein, S100A7. This study further demonstrated that TdfJ
specifically bound to the human form of S100A7 and not the mouse protein (230).
Calprotectin is an obligate heterodimer of two S100 proteins, S100A8 and S100A9, and
is found at high concentrations within the cytoplasm and the granular contents of neutrophils and
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monocytes (316,317). Calprotectin has been documented to bind to Zn, Mn, Cu, and Fe, which
contributes to its antimicrobial properties against a variety of pathogens (202-204,277,318).
Calprotectin is also abundant within NETs (299). Interestingly, N. gonorrhoeae modulates the
immune environment to upregulate a Th-17 and T-regulatory immune response and
downregulate a Th-1/Th-2 immune response. This Th-17 response drives a large influx of
neutrophils to the site of infection resulting in the classical purulent discharge associated with
gonococcal infection (57,319). N. gonorrhoeae is adept at surviving this influx of neutrophils
and their toxic effects. N. gonorrhoeae can inhibit the processes of phagocytosis, phagosome
maturation, and reduce the production of reactive oxygen species through the expression of
surface proteins (304). The phase variable nature of gonococcal LOS also allows for increased
survival in the presence of cationic peptides, which are also abundant within NETs (58). NET
production involves an irreversible expulsion of intracellular contents, which trap invading
pathogens in a hostile and toxic environment. However, N. gonorrhoeae is capable of surviving
NETs in part due to the production of a thermonuclease and the TdT, TdfH (231,298,307,320).
The most well-characterized, gonococcal metal transport system is comprised of TbpA
and TbpB, which are responsible for high-affinity transferrin binding and iron piracy. TbpA, like
other TdTs, has an N-terminal plug domain that contains a TonB box, and C-terminal β-barrel
(210). TbpA also demonstrates a host restriction for human transferrin (hTf) and is incapable of
binding to a variety of animal transferrins (214,321). The co-crystal structure of N. meningitidis
TbpA and hTf showed that a large surface area of TbpA (~2500 Å2) interacts with hTf. Further,
the co-crystal structure revealed an α-helix within one of the extracellular loops of TbpA that
was in close association with the iron-binding cleft of the C-lobe of hTf (210). Investigations into
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the function of the loop 3 helix found that a complete deletion of the structure abrogated hTf
binding and subsequent iron internalization (281).
Conservation of the gonococcal TdT systems has led to our hypothesis that other TdTs
share similar structural and functional relationships with their ligands as TbpA and TbpB have
for hTf. LbpA, which allows for iron acquisition, from human lactoferrin (hLf), resembles TbpA
structurally as it also contains an N-terminal plug domain with a TonB-box and a 22 stranded Cterminal β-barrel (217,322). Further, only expression of LbpA is required for iron acquisition
from hLf, and the expression the cognate lipoprotein LbpB, like the hTf system, makes iron
acquisition more efficient by distinguishing between apo-and holo- lactoferrin (216,217).
Interestingly, neither the TdfH nor TdfJ systems have a companion lipoprotein associated with
them (295). The S100 protein ligand for TdfH is able to bind both Zn and manganese (Mn2+) and
both hCP and S100A7 are present in high abundance in inflamed tissue (194,204,323) .
Therefore, a cognate lipoprotein that distinguishes between apo- or metal-loaded ligand may not
provide a benefit in either of these Zn systems. Both the TbpAB and LbpAB systems have been
shown to be human-restricted for their ligands and consequent iron internalization (252,324).
This commonality between TdTs is not seen only with the iron transporters but also with the Zn
transporters. The crystal structure of ZnuD, the meningococcal homolog of TdfJ, also shows
structural similarity, including a loop 3 helix similar to that of TbpA (315). The study into the
interaction between TdfJ and S100A7 of N. gonorrhoeae found the interaction to be human
specific (230).
The binding between TdfH and CP has previously been demonstrated only in the context
of whole cells and thus, it was formerly possible that other membrane factors could influence or
be responsible for the interaction (231). ITC experiments in the current study (Figure 3.5, Table
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2) were performed and allowed us to identify a unique pattern of interaction between TdfH and
CP with two binding affinities. The first interaction between WT-hCP and TdfH was determined
to be a high-affinity interaction (4.3 nM) and the second was lower affinity at 38.3 μM. In
contrast, the TdfH-mCP interactions were measured as 0.4 μM and 25.6 μM, both lower than the
high-affinity interaction seen with TdfH-hCP. The dimer of CP is capable of coordinating a Zn
atom at either site 1 or site 2 (133,136,152). Since hCP is a heterodimer, the two-state interaction
and particularly the high affinity interaction between hCP-TdfH may be due to a preference of
TdfH for either site 1 or site 2, which are present on opposite sides of the dimer interface.
N. gonorrhoeae is an obligate human pathogen with a demonstrated species restriction
for interaction between host proteins and gonococcal surface proteins including the TdTs
(230,252,325). The competition assay between hCP and mCP binding (Figure 3.2) demonstrated
no competition by mCP; however, this could have been due to the difference in the affinity of the
hCP-TdfH and mCP-TdfH interactions (Figure 3.55, Table 2). When mCP and hCP were used
independently to directly probe the surface of N. gonorrhoeae (Figure 3.3), hCP bound to strains
possessing TdfH (FA1090 and MCV662) as has been described in both N. meningitidis and N.
gonorrhoeae (231,302), while mCP binding was undetectable. Analysis of the amino acid
sequence diversity between human and mouse S100A8 and S100A9 found that both shared 58%
sequence identity and they shared 83% and 74% amino acid sequence similarity, respectively.
The observation that evolution of hTf has been driven in part by TbpA positive selection may
explain the sequence diversity found between human and mouse S100A8 and S100A9 (310).
Evolution hCP may have occurred through a similar positive selection, which has been driven by
TdfH binding to host ligand.
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The Zn-binding sites of CP are formed at the dimer interface; however, S100A8
contributes 4 of the 6 residues to the non-canonical binding site (site 1, His6), while S100A8 and
S100A9 contribute an equal number of residues to the canonical binding site (site 2, His3, Asp)
(Figure 3.6) (194,204,206,301). hCP with mutations in either metal-binding site 1 (S1KO) or
site 2 (S2KO) were used to test whether these residues contributed to the ability of TdfH to
interact with CP and whether these sites were utilized equally for Zn piracy (Figure 3.7). Growth
of N. gonorrhoeae was significantly hindered when Zn-binding was abrogated in site 1. When
the S1KO was titrated into purified TdfH, an isotherm with minimal heat release was seen, along
with two micromolar interactions. The S2KO, by contrast, resembled the WT-HCP isotherm
with one nanomolar interaction and one micromolar interaction; however, mutation of site 2 did
reduce the affinity ~15 fold. S2KO CP was capable of supporting the growth of the gonococcus
when provided as the sole Zn source. The difference in affinity and the ability to support the
growth of the gonococcus suggests that the absence of the non-canonical site (S1) of hCP
significantly hinders TdfH binding and use as a Zn source. Mutation of the canonical site (in the
S2KO) had a minimal impact on the overall affinity compared to WT-CP (Figure 3.8). Taken
together, these data suggest that the region around site 1 may be the primary interaction site
between TdfH and hCP.
In lieu of a TdfH crystal structure, we used extensive sequence and structural modeling to
form a homology model of TdfH, which offers clues for how it may interact with hCP (Figure
3.9). To validate the model itself, we did molecular dynamics simulations, which show a stable
model over the course of 100 nanoseconds within a membrane bilayer. Further, electrostatic
surface maps of the TdfH model reveal clear domain separation of the membrane belt and also
displays properties that align well with previously-crystalized meningococcal ZnuD, including
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an electropositive belt along the surface, in proximity of the membrane domain, and strongly
electronegative surface loops (Figure 3.9B). We also analyzed the electrostatics of hCP, finding
that the site 1 and site 2 regions were predominantly electronegative, making it unlikely that
those directly participate in binding at the surface loops. Rather, regions encompassing sites 1
and 2 may interact along the electrostatic belt. Interestingly, the divergent ends of hCP, which we
hypothesize may contribute most to the interaction between hCP and TdfH, were not strongly
charged (Figure 3.9C). Our homology model will allow for future studies that interrogate the
exact contributions that loops of TdfH have on the interaction with hCP. Understanding how the
TdfH loops contribute to hCP binding will also aid in directed-mutagenesis studies to abrogate
ligand binding to produce a better antigen for eventual inclusion into a vaccine for the prevention
of N. gonorrhoeae infection, similar as was seen with mutants of TbpB in H. parasuis therapies
(326). In that study, point mutations were generated that abrogated TbpBs ability to bind to
porcine Tf. The abrogation of ligand binding enables the immune system to have larger area for
antigen recognition. Furthermore, the native proteins are still capable of binding to its host ligand
and can effectively mask itself from the immune system by looking like the host. When these
mutant TbpBs were used to immunize piglets against H. parasuis, they produced a more robust
immune response compared to native TbpB, and protected piglets from a lethal dose infection.
Frandoloso et al. provided strong evidence to confirm the hypothesis that abrogating ligand
binding does produce more potent immunogens (326). Applying these directed mutagenesis
studies to gonococcal TdTs could increase their potency as a vaccine antigen.
Our study has provided a detailed view of the unique interaction between bacterial and
host proteins. Identification of a species preference for CP informs the need to generate an hCP
transgenic mouse model for further in vivo function and immunogenicity testing. Moreover, the
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finding that site 1 of hCP may be the preferential site of Zn piracy will further guide mutagenic
experiments aimed at deciphering the molecular mechanism used by TdfH to mediate
gonococcal virulence. Performing similar methods on TdfH to what has been done to mutate
TbpA (281), could define the exact residues that contribute to binding and Zn-piracy of hCP.
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Chapter 4: The Effect of Iron Stress on Antimicrobial Sensitivity and Abrogation of
Transferrin Binding Through TbpA Mutational Analysis and Small Molecule Inhibitors

I.

Introduction
Despite iron being one of the most abundant elements on earth, and an essential

component for the oxidative respiration of living organisms, the human body is almost devoid of
bioavailable iron. Host derived metalloproteins or hemoproteins, including transferrin,
lactoferrin, and hemoglobin, bind the majority of free iron in the body (293,327). Sequestration
of iron increases in an inflammatory state due to the body's hypoferremic response that induces
the production of more lactoferrin at mucosal surfaces and reduces transferrin saturation from
30% to as low as 5% (293,328). The host’s restriction of iron has been classically described as
host “nutritional immunity” and has now been extended to include zinc and manganese
restriction (129,291). Microbes can overcome this extreme metal deprivation during host
colonization by several strategies including the production and secretion of low molecular mass
iron-binding siderophores or direct removal of metals from host metalloproteins known as metal
piracy (224,329-331).
Members of the Neisseriaceae family utilize a unique strategy to overcome host
nutritional immunity involving the direct binding of host proteins and the removal of their iron
cargo (294). For example, in N. gonorrhoeae, the transferrin iron uptake system binds the host
glycoprotein transferrin through a bipartite receptor, which facilitates the removal and
internalization of iron (209). This transferrin binding and iron uptake system consists of two
proteins, TbpA and TbpB (215,321). TbpA is a TonB-dependent outer-membrane transporter
that utilizes the proton motive force and the TonB, ExbBD complex for iron import into the
periplasm (209,232,332). TbpB is a bilobed lipoprotein that selectively binds holo-human
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transferrin (hTf) and increases the efficiency of iron uptake from transferrin. In the gonococcal
genome tbpB is encoded upstream of tbpA in a bicistronic operon (332-334). Additional iron
uptake systems in the gonococcus are responsible for binding to other host-derived iron-binding
proteins including lactoferrin and hemoglobin, via LbpAB and HpuAB, respectively
(295,303,335). The lactoferrin system is only encoded by approximately 50-70% of strains due
to a deletion in lbpB, and the hemoglobin system is subject to subject to slipped-strand
mispairing and is phase off in 70% of isolates (218,336). The transferrin system of N.
gonorrhoeae has been found in 100% of isolates recovered, demonstrates limited antigenic
variation and is not subject to phase variation, which makes it a promising candidate for the
generation of a cross protective vaccine or target for disease treatment (296). An isogenic
deletion mutant of tbpA was incapable of establishing an infection in a human male volunteer
infection study, suggesting the transferrin binding system is essential for host colonization/
persistence (257). Given the phase variable nature or complete absence of other iron transport
systems in the gonococcus, the transferrin system, specifically TbpA, provides a possible target
for future vaccine development and potential treatments of gonococcal infection. The dramatic
rise of antibiotic resistance found among gonococcal isolates has pushed the classification of N.
gonorrhoeae to an urgent threat by the CDC and WHO (60). The current CDC recommended
treatment is dual therapy of 1 g oral azithromycin and intramuscular ceftriaxone (62). However,
the emergence of high levels of resistance to both azithromycin and ceftriaxone have resulted in
treatment failures, highlighting our need for developing new treatments/ preventative measures
for gonococcal disease (61,286).
Mutational studies on the homologous transferrin system of Haemophilus parasuis show
that the abrogation of TbpB’s ability to bind transferrin resulted in increased immunogenicity

93

and protection from lethal dose infection in a piglet model. Individual residues of H. parasuis
TbpB were mutated, resulting in non-binding mutants used to immunize piglets before a lethal
dose infection. Surprisingly, piglets immunized with the non-binding mutant forms of TbpB
demonstrated a 100% survival rate compared to the 25% survival rate seen when a commercially
available vaccine for H. parasuis was used (326). This study illustrated the efficacy of using
mutagenized proteins abrogated in their binding capabilities to elicit a robust and functional
immune response. Since the Frandoloso study was based on the analogous transferrin uptake
system, it was of interest to us as it may allow for the usage of the gonococcal transferrin system
as a vaccine target.
Gonococcal TbpB is highly variable and is approximately 65% similar across strains.
Meningococcal TbpB has been characterized as two distinct subtypes, which can vary in size
from 65 kDa – 85 kDa (337). Due to variability in size and sequence of gonococcal TbpB
proteins, the less variable and more conserved TbpA was selected for mutational analysis. An
alpha-helix secondary structure within loop 3 known as the loop 3 helix (L3H) illustrated the
importance of this loop structure for the binding and iron internalization of TbpA. This study
highlights the role that secondary structures of TdTs, and the amino acids within, have for both
ligand binding and metal piracy (281).
The co-crystal structure of N. meningitidis TbpA bound to hTf has allowed for the design
of new methods for treating gonococcal infection via mapping the intimate interactions that
enable TbpA binding (210). One such method is the use of small molecules that interfere with
protein-protein interactions at the interface between hTf and TbpA. A strain unable to utilize
lactoferrin as an iron source and not possessing a functional hTf-system was incapable of
colonizing and establishing an infection during a human male infection study (212). Thus,
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screening databases for small molecules that inhibit the protein interactions between TdTs and
their ligands can prove to be a powerful potential treatment for gonococcal disease. This study
investigates additional mutagenesis of the TbpA loop 3-helix and several other TbpA residues
hypothesized to contribute to the TbpA and hTf interaction Additionally this study investigates
the efficacy of small molecule inhibitors of TbpA-hTf interactions as a possible therapy.
II.

Results

A. Generation of MCV211 and MCV212
In an attempt to generate a mutated form of TbpA abrogated for its binding function, a
mutational analysis was performed on various extracellular loops of TbpA. The mutational
analysis by Cash et al. (281) on the α-helical finger of an extracellularly exposed loop from
TbpA, found that the presence and amino acid sequence of the loop 3-helix is vital for TbpA
function. Before this study, it was unclear which of the 11 surface-exposed loops played a
significant role in transferrin binding, let alone metal piracy. The determination that loop 3 did
significantly contribute to binding and removal of iron metal removal allowed for a more
directed mutational analysis for follow-up attempts at the complete abrogation of TbpA function.
However, a large surface area of TbpA interacts with the C-lobe of hTf, and Cash et al. used only
single amino acid substitutions for the loop 3-helix mutational study. Therefore, to build off the
previous research, we predicted that multiple amino acid substitutions of the loop 3- helix and
other loops predicted to interact with hTf, could entirely abrogate ligand binding not detected
with single mutations. Piliated FA19 cells were transformed with linearized pVCU191 or
pVCU192 to generate MCV210 and MCV211, respectively. pVCU191 contains truncated tbpB
and a mutated (D251A) full-length tbpA. Similarly, pVCU192 also has a truncated tbpB and a
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mutated (D251A and K359R) full-length tbpA (Figure. 4.2). Western blots confirmed the
expression of mutant TbpA from both MCV211 and MCV212 (Figure 4.1).
B. MCV210 and MCV211 exhibit reduced hTf binding
The TbpA D251A mutation in MCV210, was initially hypothesized to be the primary site
of interaction between TbpA loop 2 and hTf, by Noinaj et al., based on the co-crystal structure of
N. meningitidis TbpA with hTf. The TbpA D251A mutation exhibited a significant reduction (p<
0.05=*) in HRP-Tf binding compared to WT FA6905. Significance was determined from 3
independent biological replicates performed in triplicate by a Students t-test. In the TbpA double
mutant, MCV211 (D251A and K359R), there was no significant reduction in HRP-hTf binding
when compared to WT FA6905 as determined by a Students t-tests (Figure 4.3). The
introduction of the D251A loop 2 mutation or the D251A/K359R double mutation had a limited
effect at reducing hTf interaction that was equivalent to the single L3H mutants previously tested
via Cash et al.
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Figure 4.1

TbpA western blot of MCV210 and MCV211
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Figure 4.1 TbpA western blot of MCV210 and MCV211
Strains FA6905 (WT), FA6815 (tbpB::Ω), MCV210 (D251A), and MCV211
(D251A/K359R) were grown in a chemically defined chelex treated media for 1 hour before
back dilution and 4 hours of outgrowth. After 4 hours strains whole cell lysates were collected at
o

100,000 Klett Unit μL, suspended in 2x Laemmeli buffer and stored at -20 C. Whole Cell
lysates were subjected to SDS PAGE and transferred to nitrocellulose overnight at 28 mA. Blots
were Ponceau stained to demonstrate equal loading of protein, and probed with 1:1000 α-TbpA
o

1 , and then probed with 1:5000 goat α-rabbit IgG conjugated to horseradish peroxidase. The blot
was developed with 4-chloro-1-naphthol/3,3'-diaminobenzidine tetrahydrochloride (CN/DAB
substrate kit, ThermoFisher). FA6905, MCV210, and MCV211 all expressed TbpA while
FA6815 did not.
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Figure 4.2

Schematic of pVCU191 and pVCU192 used to generate MCV210 and
MCV211
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Figure 4.2

Schematic of pVCU191 and pVCU192 used to generate MCV210 and
MCV211.

The creation of MCV210 and MCV211 was achieved through the shuttle vector of
pVCU191/192. These plasmids contain a deleted region of tbpB (tbpBΔ), full length tbpA and
DNA sequence immediately downstream of the tbpA coding region which contains a mTn3Cat
for a means of selection. pVCU191 possess a tbpA gene sequence with a D to A mutation at the
251 amino acid residues. pVCU192 possess a tbpA sequence that also contains this D251A
mutation with an additional K to R mutation at the 359 amino acid residues. Gonococcal
transformation with linearized pVCU191 and pVCU192 can result in two major possibilities.
The first outcome is produced via a double cross over event in the tbpBΔ and in the downstream
r

sequence of tbpA resulting in the genotype of the gonococcus being tbpBΔ tbpA+ Cm . The
second possible outcome results from a double cross over event occurring in the tbpA sequence
r

and in the downstream sequence of tbpA resulting in full length native tbpB tbpA+ Cm . Figure
amended from Cash D.R. et al.
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Figure 4.3

Mutant TbpA-hTf Binding ELISA
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Figure 4.3

Mutant TbpA-hTf Binding ELISA

Iron starved gonococci grown on GCB media supplemented with 50 μM desferal were
plated in 96 wells plates and probed with 12.5 nM HRP-hTf similar to previously-described
methods and according to the manufacture’s recommendations [Jackson Immunoresearch,
(281)]. MCV210 contains an aspartic acid to alanine mutation at the 251 amino acid residue
(D251). MCV212 has the same D251A mutation and an additional lysine to arginine change the
359 residue (K259R). MCV168 was used as an internal control as it had been previously
published to have a significant reduction in HRP-hTf binding. MCV210 demonstrated an almost
30% reduction in HRP-hTf binding. MCV211 had an ~20% reduction in HRP-hTf binding, it
was not statistically significant as determined by a Students t-test, error bars represent SEM.

102

C. Small molecule inhibitors of TbpA
Co-crystallization of Neisseria meningitidis TbpA in complex with hTf opened the
doorway to a possible new means to treat gonococcal infections through the newly-gained
insights into the intimate interactions of TbpA and hTf. Through a collaboration with Dr. Glen
Kellogg at Virginia Commonwealth University, we virtually screened various databases of small
molecules with the potential to disrupt the interaction between TbpA and hTf. Molecules were
chosen based on their potential to fit in the binding pockets between TbpA and hTf (Figure 4.4).
The original screen resulted in 15 candidates predicted to inhibit TbpA-hTf interaction at two
potential sites. Putative compounds were chosen based off their hydrophobic interactions (HINT)
scores, which are used to describe and quantify all possible biological interactions. HINT scores
are multifactorial and include various biological interactions such as coulombic, hydrogen
bonding, and hydrophobic interactions between the two molecules. The higher the HINT score,
the more favorable the interaction between the small molecule and TbpA. The second screen of
small molecules looked at the crystal structure of TbpA with the amino acid sequence of LbpA
threaded through the crystal structure. This new analysis resulted in 16 compounds with
predicted HINT scores suitable to disrupt the interaction of either TbpA or LbpA with their
respective ligand and elucidated a potential third small molecule interaction site cross-reactive
for LbpA and TbpA. The efficacy of these 16 compounds to disrupt hTf interaction with TbpA
was determined via a modified transferrin binding ELISA.
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Figure 4.4 Location of small molecule binding site I and II
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Figure 4.4

Location of binding site I and II.

TbpA co-crystal structure is show as a cartoon representation with colored secondary
structures. α- helicies are shown in red, β-sheets are shown in in yellow and loop structures are
shown as green. Transferrin is shown as a stick representation (grey) bound to TbpA with the
putative small molecule binding site I shown in blue, site II shown in red. (PDB ID 3V8X)
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In order to determine the sole contribution of our TbpA mutations, all of the strains used
were in the FA6905 background (-tbpB) to eliminate TbpB binding to hTf. FA6905 was used as
our positive control for hTf binding since it still expresses a function TbpA capable of interacting
with hTf. FA6815 possess an Ω cassette in tbpB and prevents the expression of the transferrin
acquisition system, and was used as a negative control due to the strains inability to interact with
hTf. FA6905 and FA6185 were iron starved overnight by growth on GCB plates supplemented
with 5 μM desferal before being resuspended and then added to a poly-L-lysine-coated 96-well
microtiter plate. Compounds TL1 – TL16 were diluted in dimethyl sulfoxide (DMSO) to a stock
concentration of 5 mM or 10 mM and added to the plate at 100 μM final concentration. DMSO
served as a negative control illustrating a lack of hTf inhibition, while excess unlabeled Tf
(comp) served as a positive control for the experiments. Compounds TL1- TL3 inhibited HRPhTf binding to whole gonococci the least, showing no significant reduction compared to
FA6905. Compounds TL5- TL7, TL-9 and TL-10 significantly decreased HRP-hTf interaction
to whole gonococci, exhibiting a ~15-20% reduction in hTf binding to the surface of the
gonococci (Figure 4.5A). Surprisingly, while TL11- TL16 had no significant decrease in HRPhTf binding to the whole cells, these compounds slightly increased the interaction between hTf
and the gonococcus (Figure 4.5B). These experiments could serve as a proof of principle for
using small molecules to inhibit the receptor-ligand interaction could be a possible means of
treatment for gonococcal infection.
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Figure 4.5A. Small Molecule inhibitors of TbpA ELISA with Compounds TL1- TL10.

Figure 4.5B. Small Molecule inhibitors of TbpA ELISA with Compounds TL11- TL16.
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Figure 4.5. Small molecule inhibitors of TbpA ELISA with compounds TL1- TL10.
A.) Gonococci grown on GCB Media containing 5 μM desferal, an Fe chelator, for Fe
starvation overnight. Cells were resuspended to a final OD600 of 1.0 in PBS and transferred into a
96 well plate. Cells were incubated at room temp for 1h before cultures were blocked and treated
with compounds TL1- TL10. Small molecules were in the plate for 1h and then probed with 12.5
nM HRP-hTf for 1h, washed, and developed with TMB ELISA substrate (ThermoFischer).
Compounds TL-1, TL-2, and TL-3 had no significant reduction in binding when compared
DMSO vehicle treated controls. TL-5 thru TL-7 and compound TL-9 and TL-10 demonstrated a
significant reduction in HRP-hTf binding to the surface of the cell compared DMSO vehicle
treated controls. TL-9 and TL-10 illustrated the greatest reduction in HRP-hTf binding, reducing
HRP-Tf interaction by ~20%. B.) Compounds TL11- TL16 demonstrated little to no reduction in
HRP-hTf binding; in fact, compounds TL14-TL16 increased HRP-hTf deposition to the surface
of the cell. Significance was determined by a Students t-test (p< 0.05=*).
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III.

Discussion
The lack of a protective immune response and the continuing prevalence of gonococcal

infections has made the need for an effective vaccine a top priority worldwide. Numerous
attempts have been made, but due to the vast antigenic variation exhibited by N. gonorrhoeae, no
efforts have been successful. However, the TonB-dependent transporters (TdTs) of the
gonococcus have vaccine potential; specifically, TbpA is of particular interest, due to its lack of
antigenic variation and conservation among all gonococcal isolates. A strain lacking TbpA
expression, attenuated in its ability for colonization in a human male infection model, gives even
more interest in further characterizing this protein for its vaccine potential (212). In 2012, the cocrystal structure of N. meningitidis TbpA with hTf was resolved. N. gonorrhoeae TbpA shares
95% sequence identity with N. meningitidis, and this co-crystal structure has furthered our
understanding of how TbpA interacts with hTf (210).
Frandoloso et al. discovered that abrogation of interaction with host protein increases the
immunogenicity of TbpB of H. parasuis in a piglet infection model. This led us to hypothesize
that mutagenizing gonococcal TbpA so that it no longer interacted with human Tf would
similarly result in increased immunogenicity and possibly protection. Cash et al. generated
mutants in the L3H that were hypothesized to play a key role in iron removal from hTf. That
study mutated the polar amino acids found within the L3H to characterize their role in hTf
binding and iron removal. The mutation with the most significant phenotype was the terminal
lysine residue of the L3H (K359), which resulted in a significant reduction in binding to hTf. The
decrease in hTf binding also resulted in an overall reduction in iron accumulation into the cell.
Therefore, we predicted that multiple mutations, one present in the L3H and a second mutation
in loop 2, would further reduce or abrogate the ability of N. gonorrhoeae to bind to hTf.
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The K259R mutation of the study by Cash et al. had been previously described as having
reduced WT hTf binding capabilities (281), while the D251A mutation located in loop 2 was
hypothesized to be 1 of the 87 amino acids that interact with hTf by Noinaj et. al (210).The
D251A mutation alone resulted in almost 30% reduction from WT levels of binding to human
transferrin. Interestingly, the combining mutations D251A/ K359R in MCV212 did not have an
additive effect on the overall hTf binding. Despite the limited reduction in hTf association, only
two mutations were analyzed in this study, which were selected based either on previouslyobserved ability to reduce hTf binding or a hypothesized interaction with hTf. The D251A and
K359R mutations were also not present on the same loop or secondary structure, and their lack
of proximity may have reduced their cumulative effects since such a large surface area of TbpA
is thought to interact with hTf (210). The generation of multiple mutations across the surface of
TbpA may further reduce the interaction of TbpA to hTf, as the surface area that is projected to
interact between these two proteins is substantial. Further optimization of this study is currently
ongoing with an extended survey of the function of the L3H via the introduction of prolines
along the length of the helix. Loop 5 and loop 10 of TbpA have also demonstrated the ability to
bind to hTf independent of the β-barrel and could also be coupled with the current mutations to
abrogate hTf binding capabilities.
While the ultimate goal of our study is to continue investigating the potential of TbpA as
a vaccine antigen, the dwindling rate of treatment options for gonococcal diseases poses a severe
threat (286). Inhibition of the TbpA-HTf interaction can lead to a reduction in iron uptake into
the cell. The co-crystal structure of the TbpA-hTf complex has allowed for the new innovative
approaches at treating gonococcal disease including the use of small molecules that could
interfere with the ability of TbpA to bind to hTf. An initial screening of TbpA’s structure against
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a small molecule database to identify compounds that inhibited the interaction between TbpA
and hTf, identified 14 compounds with HINT scores suitable to potentially disrupt TbpA-hTf
interactions with hTf. Testing these compounds for their ability to disrupt binding revealed that
there was potential for these compounds to reduce TbpA-hTf interaction. A modest reduction
was seen with two out of the 14 compounds tested; however, some of these compounds also
increased the apparent interaction between hTf and TbpA (338). The second screening of small
molecule database conducted utilized both the structure of TbpA and the amino acid sequence of
LbpA threaded through the TbpA for its analysis. This screen found 16 putative compounds with
HINT scores suitable to disrupt not just hTf interaction with TbpA but also hLf with LbpA. This
approach may identify a new and innovative treatment option for gonococcal disease because a
single compound could potentially disrupt two of the major iron uptake systems essential for the
gonococcus survival in the host (212).
Similar to the previous small molecule study done by Dr. Devin Cash, ELISAs accessing
the levels of transferrin binding identified a modest reduction with 7 out of the 16 compounds
tested. The most significant inhibition of HRP-hTf binding was from compound TL-9
(Z45647810), which demonstrated about a 20% inhibition of hTf binding (Figure 1.4). These
compounds still require optimizing. Modifying side chains of these compounds to mimic those
naturally found in hTf may increase their solubility and stability, leading to a level of inhibition
required for iron starvation. The level of hTf binding inhibition would need to be over 80-90% of
WT TbpA to sufficiently starve the gonococci of iron if used independent of other antibiotics,
but could have more modest inhibition if used as a therapy in conjunction with antibiotics (281).
However, these compounds still require testing for the LbpA system to determine their reductive
capabilities for the two systems. A putative third binding pocket of TbpA for these compounds
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was also identified in the second screening of the small molecule databases, and a collection of
the various site inhibitors needs to be tested as a multidrug inhibitor.
These compounds were selected for their ability to hydrophobically interact with TbpA.
Therefore, attempts to modify these compounds chemical moieties to allow for increased ionic
interactions may result in retention within these binding pockets, increasing the inhibitory nature
of these molecules. Overall, the inhibition of the hTf-TbpA interaction from these small
molecules was modest; however, continued testing of these compounds and others, alone and in
combination, could reveal a new treatment for gonococcal disease if the right type and
combination of compounds are determined.
A recent case of untreatable gonorrhea leaves a bleak outlook for the future of antibiotics
as an effective treatment for the disease (339). Treatment with 250 mg intramuscular ceftriaxone
and 1 g oral azithromycin, the currently recommended therapy, failed to treat and clear the
infection. Characterization of this highly resistant strain revealed high levels of resistance to both
azithromycin and ceftriaxone, the one of the first characterized strains of its kind. Our current
study with the small molecule inhibitors of TbpA and LbpA shows potential for the inhibition of
TbpA function through these compounds.
Our studies of TbpA have added to the knowledge and understanding of gonococcal
TbpA function. The knowledge that a loop 2 mutation decreased ligand binding may allow for
future mutagenesis across the various loops that, in conjunction with the current mutations, may
abolish hTf binding by TbpA. An increased focus on the L3H mutations which disrupt the helical
structure coupled with other loop mutations may ultimately provide a non-binding or nonfunctional form of TbpA which still retains its native conformation. These non-binding TbpA
mutants potentially deployed with non-binding forms of TbpB, could represent an effective
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vaccine with increased immunogenicity from the TbpB and cross-protection from TbpA. While a
vaccine for the gonococcus is still the primary focus of our research, it cannot be forgotten that
the continued prevalence of antibiotic resistance continues to increase every day. The recent case
of an azithromycin and ceftriaxone resistant infection in the UK is likely the first of many to
occur and, as such, new treatment potentials are desperately needed. The small molecule
inhibitors of TbpA highlight a novel approach for the treatment of gonococcal disease and have
the potential to be used as a stand-alone treatment or added with current therapies to treat
resistant isolates.
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Chapter 5: Analysis of the Putative Heme Exporter MacA in N. gonorrhoeae

I.

Introduction
Hemoglobin, heme, and other heme-containing moieties constitute the majority of bio-

available iron that pathogens use during infection, with more than 70% of the iron in humans
contained within heme (158,292,340,341). Hemoglobin utilization and heme acquisition systems
have evolved across a broad range of pathogenic bacteria to utilize this pool of bioavailable iron
(327,340,342,343). Heme is a part of cytochromes in the electron transport chain (ETC), and the
iron-bound to heme is used by enzymes as a cofactor and is an essential component of redox
reactions and cellular respiration (159,340-342). Heme and heme-derivates are endogenously
synthesized by Neisseria species, specifically N. gonorrhoeae and N. meningitidis, with the final
step of synthesis being Fe3+ loading onto protoporphyrin IX (PPIX) catalyzed by HemH
(344,345).
Excess heme has the potential for toxicity to both the pathogen and host due to
production of reactive oxygen species (ROS) and to its lipophilic nature (346-348). Heme import
and production in N. gonorrhoeae are tightly controlled. Endogenous heme synthesis is
regulated by a negative feedback loop in Escherichia coli, Staphylococcus aureus, and
Salmonella enterica, involving PPIX-Fe inducing proteolytic degradation of the heme synthesis
gene products , HemA, and HemH (344,349). N. meningitidis possess heme and hemoglobin
uptake systems, HmrB and HpuAB respectively, and are both under Fur-regulation
(144,220,223). Similarly, the gonococcal TonB-dependent transport system HpuAB is also
tightly controlled by Fur and N. gonorrhoeae can utilize hemoglobin and hemoglobinhaptoglobin complexes through the HpuAB (228,350). The gonococcus has no known dedicated
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heme importer, but N. gonorrhoeae is capable of using heme as a sole iron source in a TonBindependent manner (295).
Since heme has the potential for toxicity, N. gonorrhoeae has systems involved in
detoxifying the protoporphyrin ring, or expelling excess heme from the cell. Bacterial efflux
pumps maintain cellular homeostasis in toxic or otherwise hostile environments and can aid in
the delivery of effectors to the extracellular tissue, which promotes pathogenicity. Pathogens that
colonize and infect humans encounter host defenses and noxious compounds regularly and if
maintained at high cellular levels results in bacterial cell death (351,352). Exporters of these
potentially toxic compounds are energized in two ways. One way uses the proton motive force to
stimulate the active transport of materials out of the cell, while the other uses intracellular energy
in the form of ATP (353-355). Unlike most bacterial pathogens, there are few efflux pumps
identified in the genome of N. gonorrhoeae, with MacA annotated as a macrolide exporter and a
putative transporter for heme export (353,356). MacA interacts with TolC found in the outermembrane of E. coli and N. gonorrhoeae. The MacA-TolC channel is energized via the ATPase,
MacB, creating a tripartite efflux pump initially identified to transport macrolide antibiotics out
of the cell (353,357). E. coli MacAB has been shown to export heme from the cell and deliver
enterotoxin II to the extracellular environment aiding in E. coli colonization and pathogenesis
(352). Targeting a potential pathway for heme extrusion could be a possible new
chemotherapeutic treatment for gonococcal disease or disseminated infection given the
dwindling options for treating gonococcal disease. Through a collaboration with Dr. William
Shafer at Emory University, we sought to determine if the efflux system, MacAB, was crucial in
heme export from N. gonorrhoeae.
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II.

Results
Strains FA19 (WT), macA::kan (MacA KO), and two MacA complementation strains,

pGCC3+::macAC and pGCC4+::macAC, were provided to us by Dr. Shafer. pGCC3+::macAC and
pGCC4+::macAC inserts MacA at an ectopic site within the chromosome and contains two
promoter operator sequences allowing for IPTG control of gene transcription. Strains were
grown overnight on GCB media supplemented with 50 μM desferal for overnight iron starvation
before inoculation into CDM. Cells were grown for around one hour before back diluting in a
CDM mixture containing 2.5 µM apo-bTf as an iron chelator and plating into a 96-well plate
containing various dilutions of heme (5 μM, 10 μM, 15 μM, and 25 μM heme), 30% saturated
hTf, or 30% saturated bTf as iron sources, and 1 mM IPTG. Strains were grown for six hours
with hourly time points taken (Figure 5.1-Figure 5.4).
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Figure 5.1 Heme-dependent growth of N. gonorrhoeae with 25 μM heme
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Figure 5.1

Heme-dependent growth of N. gonorrhoeae with 25 μM heme
C

Strains FA19 (WT) , macA::kan (MacA KO), pGCC3+ macA , and pGCC4+ macA

C

were grown overnight on GCB supplemented with 5 μM desferal before inoculation of a trace
metal free flask. Strains were grown until doubling before back dilution with CDM containing
2.5 μM apo-bTf for free iron chelation. Back diluted strains were plated in a 96-well plate with
25 μM heme, 2.5 μM 30% saturated hTf as a positive control, or no iron source as a negative
o

control. Bacterial cultures were incubated at 37 C with 5% CO2 for 6 hours with hourly OD
readings. No significant difference seen between strains FA19, MacA KO, or either MacA
complementation strains. Every strain, with the exception of pGCC4+, was significantly different
from FA19 grown with apo-bTf (p< 0.05= *). Statistical analysis performed via a two-way
ANOVA with Tukey’s multiple comparisons post-hoc test. Error bars represent standard error of
the mean (SEM).
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Figure 5.2

Heme-dependent growth of N. gonorrhoeae with 15 μM heme
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Figure 5.2

Heme-dependent growth of N. gonorrhoeae with 15 μM heme

Bacterial strains were grown, back diluted, and plated as in figure 2.1 and grown in the
presence of 15 M heme. No significant difference seen between stains FA19, MacA KO, or
either MacA complementation strain. Every strain was significantly different from FA19 grown
with apo-bTf (p< 0.05= *). Statistical analysis performed via a two-way ANOVA with Tukey’s
multiple comparisons post-hoc test. Error bars represent SEM.
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Figure 5.3

Heme-dependent growth of N. gonorrhoeae with 10 μM heme
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Figure 5.3

Heme dependent growth of N. gonorrhoeae with 10 μM heme.

Bacterial strains were grown, back diluted, and plated as in figure 2.1 and grown in the
presence of 10 μM heme. No significant difference seen between stains FA19, MacA KO, or
either MacA complementation strain. Every strain was significantly different from FA19 grown
with ap-bTf (p< 0.05= *). Statistical analysis performed via a two-way ANOVA with Tukey’s
multiple comparisons post-hoc test. Error bars represent SEM.
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Figure 5.4 Heme-dependent growth of N. gonorrhoeae with 5 μM heme
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Figure 5.4. Heme-dependent growth of N. gonorrhoeae with 5 μM heme.
Bacterial strains were grown, back diluted, and plated as in figure 5.1 and grown in the
presence of 5 μM heme. Every strain was significantly different from FA19 grown with apo-bTf
(p< 0.05= *). Statistical analysis performed via a two-way ANOVA with Tukey’s multiple
comparisons post-hoc test. Error bars represent SEM.
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We hypothesized that the MacA KO strain would be defective for growth as compared to
strains grown in 30% saturated hTf. However, the MacA KO showed no reduction in growth for
all the heme dilutions tested compared to the positive control. The MacA KO mutant consistently
grew at the same rate and to a similar final OD600 as the WT and complemented strains. The 5
μM heme concentration did exhibit slightly reduced growth for all strains when compared to the
positive control, but is possibly an artifact of the reduced iron availability to the iron starved
gonococci.
Ferrochetelase, or hemH, is responsible for the catalytic addition of Fe3+ to heme and
heme derivatives within cells (345). The lack of any growth defect in the MacA KO mutant led
us to question if the ability to load endogenous heme by hemH was mitigating the toxicity of the
heme concentrations used, and thus we sought to generate a double mutant of MacA KO and
hemH::Cat. Unfortunately, transformants were not able to be recovered, which may have been
due to the essential roles that both macA, and hemH have together for the gonococcus. Taken
together these heme growth assays strongly suggest that MacA is not an exporter of intracellular
heme for N. gonorrhoeae.
I.

Discussion
Heme plays a crucial role in survival, colonization, and pathogenesis for many bacterial

species, but can also pose a threat to bacterial cells incapable of regulating its import, export, or
production (329,340). When heme is present at high concentrations in a bacterial cell, it can
generate harmful ROS and can insert itself into membranes due to its lipophilic nature (346,348).
Recently, studies have identified a heme efflux pump in E. coli, MacAB (344). MacAB was
initially annotated as an antibiotic efflux pump for macrolide antibiotics in several pathogenic
species (353,358,359). MacA forms a periplasmic channel interacting with TolC to generate a
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channel spanning from the inner-membrane to the outer membrane of the bacterial cell. MacB
has ATPase function and energizes the MacA-TolC complex to expel macrolides and heme out
of E. coli (344,353). Pathogenic Neisseria, like many other pathogens, can directly import heme
via outer membrane receptors. N. gonorrhoeae has a hemoglobin transporter, HpuAB, which
binds to hemoglobin and transports heme into the cell (360-362). Growth assays of an isogenic
mutant with an inactivated MacA were used to test if the MacAB system of N. gonorrhoeae
plays a similar role to that of E. coli.
A deficiency in the growth of the MacA KO mutant strain would have been evidence for
a role that MacA is an exporter of heme for the gonococcus. The dilutions of heme were chosen
to show toxicity at lower dilutions, given the documented inhibitory concentration of around 25
μM heme in N. meningitidis (363). Over the six hours of growth in the presence of either 25 μM,
15 μM, 10 μM, or 5 μM heme, the MacA KO strain demonstrated no significant reduction in
growth under the conditions tested. The MacA KO mutant grew as well as the positive control
strain for all dilutions except for 5 μM heme. Stains grown in 5 μM heme as the sole source of
iron had a lower final OD600 and slower growth compared to the positive control grown in 2.5
μM hTf. All of the strains, including the WT, showed reduced growth in 5 μM heme, which may
be due to the lack of iron availability in the iron starved cells. Since heme requires proteolytic
degradation for pathogens to access the Fe3+, there possibly was not enough heme to allow for
maximal growth. Further, hemO, which encodes heme oxygenase, is responsible for the
proteolytic degradation of heme allowing for iron access and detoxification of the protophoryin
ring, was still present in the MacA KO strain (344,364). The degradation of imported heme by
HemO may have reduced the toxic accumulation occurring from the lack of heme export through
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MacA; therefore, future experiments should be conducted with a double hemO macA mutant
strains to determine if MacA is responsible for in vitro efflux of heme in N. gonorrhoeae.
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Chapter 6 Perspectives and Future Directions
The rate of gonococcal infections has been steadily increasing worldwide. In the United
States alone, there were over 500,000 confirmed cases with an estimated 800,000 cases of
gonococcal infection in 2018, as reported by the CDC (45). The increase in gonococcal
infections causes an increased financial burden on the health care of infected individuals (365).
Even more concerning is the growing number of strains exhibiting high levels of resistance to
clinically useful antibiotics [(60,286), Table 3]. The recent isolation of a gonococcal strain in the
United Kingdom, which exhibited extensive resistance to the current dual therapy, ceftriaxone,
and azithromycin, means that the potential for untreatable gonorrhea is now a reality (339). The
growing concern of untreatable gonorrhea can be seen in the recent characterization of N.
gonorrhoeae as an urgent threat by the CDC.
To combat the growing risk of antibiotic-resistant gonococcal isolates, continued
investment in the development of new antibiotics is crucial. Several promising candidates are in
the developmental pipeline and are at various stages of development, with solithromycin being
the furthest along. Solithromycin (CEM-101) is a fluoroketolide that inhibits the 50S ribosomal
subunit. Solithromycin was found to have a MIC range of 0.001-32 μg/ mL against over 200
gonococcal isolates, which is lower than other macrolides, like the currently prescribed
azithromycin (366). However, some issues have arisen during its on-going phase III clinical trial
testing the effectiveness of solithromycin as a therapeutic for gonococcal infection (367). A
study comparing solithromycin to the current recommended dual therapy, ceftriaxone, and
azithromycin, found that after 7 days, solithromycin was inferior in treating uncomplicated
gonococcal urethral infection (367). Despite the setback in the development of solithromycin as a
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new treatment for N. gonorrhoeae, the phase III trial is still on-going and has, so far, the best
potential as a new treatment for uncomplicated gonococcal infections.
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Table 3 Antibiotics and Gonococcal Resistance Mechanisms
Drug Class

Resistance Mechanism (371)
Alteration of penicillin-binding proteins (PBPs)
Plasmid encoded production of penicillinases
Penicillin

Alteration of porins that limit penicillin influx
Changes in Mtr efflux pump expression
Mutations in PBPs
Alteration of porins limiting cephalosporin influx

Cephalosporins

Changes in Mtr expression
Mutations in the 23s ribosomal subunit

Macrolides
Fluoroquinolones

Alteration in efflux pump expression
Mutations in topoisomerases II and IV
Expression of TetM, protection protein
Alterations of the target structure

Tetracyclines

Alterations in porin that limit tetracycline influx
Changes in efflux pump expression
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Another of the promising new drug candidates is the new DNA gyrase inhibitor
Zoliflodacin (AZD0914), which has completed phase II trials and begun phase III. Zoliflodacin
is a spiropryimidinetrione, which is a novel derivative of a quinolone drug and was found to have
high in vitro activity against over 250 gonococcal isolates, including extensively drug-resistant
strains (368). In the phase II clinical trial, patients suffering from uncomplicated urogenital,
rectal, and pharyngeal infections were given a 3 g single-dosage of Zoliflodacin. The 3 g singledosage was able to cure 100% of rectal infections and 96% of urogenital infections; however,
Zoliflodacin was less able to cure patients with pharyngeal infections (82%) compared to
patients who were prescribed ceftriaxone (100%) (369). Even though Zoliflodacin was less able
to treat pharyngeal infections it still has potential to treat rectal and urogenital gonococcal
infections and, phase III clinical trials are now underway. While the current drugs in clinical
trials are the closest to being effective treatments for gonococcal infections, investing more
research into the discovery of new antibiotics is still of paramount importance. The newly
discovered antibiotic darobactin was found to have both in vitro and in vivo efficacy against
Gram-negative pathogens (370). Darobactin acts against the outer-membrane protein BamA,
which effectively inactivates the Bam complex and presents a novel mechanism of action (370).
There is much work left to be done with these new drugs to fully determine their efficacy as a
treatment option for gonococcal infection, particularly in more complex cases of infection, but
they are promising as the potential for untreatable gonococcal disease becomes a reality.
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Including the drugs in clinical trials, there are several other drugs currently being studied
with promising in vitro data. However, these compounds belong to drug classes that the
gonococcus has developed some resistance too (371). In order to prevent gonococcal infections,
the development of a preventative gonococcal vaccine must occur. This study investigates the
potential of a TonB-dependent transporter as a target for novel drug development. Specifically,
we sought to target the Tbp system of the gonococcus, given its importance to infection (212).
We further investigated the potential of another TdT as a vaccine candidate by investigating the
structural and functional relationship to the Cp-Zn acquisition system, TdfH, for the potential
addition to a multi-component gonococcal vaccine. The small molecule inhibition of hTfbinding to TbpA, while minimal, shows promise. These small molecules could be modified to
better inhibit the interaction between TbpA and hTf, which could lead to a promising treatment
option. The ability of our first-generation small molecules, which have undergone no additional
modifications, to inhibit hTf binding to TbpA even minimally is a proof-of-concept that these
small molecules are potentially able to be a new therapeutic. However, extensive work will need
to be done to tailor these molecules further to inhibit binding to between TbpA and hTf to the
degree needed to limit the growth of the gonococcus.
A growing body of evidence shows that presenting host binding proteins as "naked"
antigens, which are unbound by ligand, elicits a better immune response and produce antibodies
that are cross-protective and bactericidal compared to their native forms (326,372,373). Our
mutational analysis of TbpA using mutations present in the L3H and in loop two was a follow up
of the TbpA analysis by Cash et al. (281), which found that the L3H was important to binding
and use of hTf. The study also determined that single residue charge changes of the L3H amino
acids were not sufficient or capable of reducing hTf binding enough to inhibit the growth of N.
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gonorrhoeae. Our study introduced an additional mutation in loop two of TbpA, which was
predicted to have an intimate interaction with hTf (210). Despite the predicted intimate
interaction of the D251 residue, we were only able to measure at best a 30% reduction of hTf
binding, even when added to the K359R L3H mutation (Figure 4.3). Other mutational studies
are currently underway that utilize proline mutations meant to disrupt the L3H but maintain the
overall structure of TbpA in order to generate the best possible candidate for the inclusion into a
gonococcal vaccine.
The co-crystal structure of TbpA and hTf has informed much of our experimental design
in the mutational and small molecule experiments (210). Studies elucidating the crystal structure
of the gonococcal CP binding and Zn piracy protein, TdfH, is currently underway by our coauthor Dr. Nicholas Noinaj but is still unresolved. N. gonorrhoeae upregulates a Th17 response
to drive neutrophils to its site of infection (57). Interestingly, CP is one of the most abundant
cytosolic and granular proteins of a neutrophil (297). TdfH also allows the gonococcus to survive
when trapped inside of NETs by being able to overcome the high levels of metal sequestration of
the NET environment through its ability to hijack Zn from CP (231). Thus, the CP-gonococcal
interaction provides an explanation, at least in part, as a reason that the gonococcus drives
neutrophils to the site of infection, which "delivers" an extremely abundant Zn source that the
gonococcus can hijack (231).
The combined lack of a TdfH crystal structure and the critical role TdfH may have for
gonococcal survival during infection prompted us to evaluate the structural and functional
relationship of TdfH and CP. Our studies determined that mouse CP was unable to support the
growth of the gonococcus when it was supplied as the sole Zn source. Furthermore, like most of
the other gonococcal TdTs, the human form of CP was able to interact with the gonococcus
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while the mouse form of CP could not, and that interaction was determined to be high affinity
[(4.0 nM), Figure 3.5]. CP is unique among S100 proteins due to its preference for S100A8 and
S100A9 to heterodimerize (297). This heterodimerization creates two distinct transition metalbinding sites, with one metal-binding site being canonical to those found among other S100
proteins and the second being unique to CP (194,204). Our study determined that Zn piracy
occurs from the unique, non-canonical binding site of CP as gonococci grown with a mutant
form of CP where that site was unable to bind metals was deficient for growth (Figure 3.7). The
non-canonical transition metal binding site is also capable of sequestering Mn and several other
transition metals with high affinity and could thus potentially mean that TdfH is a transporter of
metals aside from Zn (203,204,301). However, preliminary data shows that Mn plays an
insignificant role in the overall growth of the gonococcus, and thus, more investigations will be
needed to determine if TdfH is only a Zn transporter or if it can import other transition metals
that may be bound to CP. In the absence of a crystal structure for TdfH, we generated a
homology model and predicted loops and beta-strands presented as a 3D structure (Figure 3.9).
This homology model gives us a starting point moving forward of where extracellularly available
loops that may play an integral role in the interaction with CP are, and may allow further
structure-function studies aimed at parsing out the loops that are critical to TdfH-CP interaction.
The knowledge that metal piracy is occurring from the non-canonical metal-binding site and our
generation of a homology model can also inform future mutagenesis experiments, similar to
those that have been performed on the Tbp system, which could result in the inhibition of ligand
binding and consequent Zn piracy (281). Since TdfH is primarily produced by the pathogenic
Neisseria, a non-ligand binding version of TdfH could be included in a cocktail vaccine and
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would leave the commensal Neisseria population intact while being cross-reactive for most of
the strains of N. gonorrhoeae and N. meningitidis.
In our final project of this study, we moved away from the targeting of TonB-dependent
transporters and focused on a known efflux pump of the gonococcus. MacA is a macrolide
exporter of N. gonorrhoeae, and it was initially found to export macrolide antibiotics out of the
cell. Recent reports have found that MacA also contributes to limiting heme toxicity by
exporting heme out of the cell in the Gram-negative pathogen, E. coli (344). Heme plays an
essential role in energy acquisition and is a component of cytochromes of the ETC (342).
However, heme is a double edge sword, and maintaining an appropriate concentration inside the
cell mitigates the harmful toxicity that high concentrations of heme have (160). Our preliminary
data of a MacA deficient gonococcal strain, which were grown on increasing concentrations of
heme, found that MacA played no role in exporting heme out of the cell (Figure 5.1-5.4).
However, further studies into MacA will be needed to determine if this gonococcal exporter has
a role in heme homeostasis for N. gonorrhoeae
Taken together, these studies provide further structure and functional knowledge of the
TdTs of N. gonorrhoeae and provides more evidence of the potential that targeting TdTs have as
a therapeutic or vaccine antigen to prevent future gonococcal disease. Understanding the intimate
protein-protein interactions between TdTs and their respective ligands will allow a more detailed
analysis of protein structures that are critical for function. Gonococcal TdTs remain highly
valued for their potential use as vaccine antigens due to their lack of high-frequency phase or
antigenic variation, conservation across strains, and their importance to the virulence of the
gonococcus. These findings have the potential to be the building blocks for future studies aimed
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at the development of protective gonococcal vaccine and therapeutics for the treatment of
gonococcal disease as infections continue to rise and may soon be untreatable.
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